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ABSTRACT 
 
Expression of the cytosolic phospholipase A2 isozymes in the human breast cancer cell 
line models MDA-MB 231 and MCF-7 and the normal breast cell line model MCF-10A. 
Debolina Ganguly 
Breast cancer remains one of the leading causes of cancer related death among women 
worldwide.  Numerous reports have provided evidence of a role of inflammation in the onset 
and progression of many cancers, including breast cancer.  A mechanism that leads to 
inflammation involves the arachidonic acid (AA) pathway, which leads to the production of a 
group of pro-inflammatory bioactive lipids, collectively known as the eicosanoids.  Despite 
evidence of AA and the eicosanoids in cancer, limited work has been done on the enzyme 
cytosolic phospholipase A2 (cPLA2) that provides the unesterified AA that can be used for 
eicosanoid generation.  The present studies were undertaken to investigate the expression of 
the cPLA2 isozymes cPLA2α, -β, -γ, in the human breast cancer cell lines MDA-MB 231 and 
MCF-7, and in the immortalized non-tumorigenic human breast cell line MCF-10A.  
Additionally, surgically removed cancerous human breast tissue was also assessed for cPLA2 
isozyme expression.  The present study indicates the presence of the cPLA2 isozymes -α, -β, -
γ in the tumorigenic breast cancer cell lines MDA-MB 231 and MCF-7.  The isozymes were 
not detected in the non-tumorigenic MCF-10A cell line.  Stimulation of the cells by Ca
2+
 
ionophore A23187 elicited a redistribution of the Ca
2+ 
dependent cPLA2 isoforms -α and -β 
within the MDA-MB 231 and the MCF-7 cells.  AACOCF3, a cPLA2αinhibitor, 
pretreatment caused a decreased cPLA2α signal, observed also in assays of cPLA2β and 
cPLA2γ.  Assays of cPLA2 isozyme expression in the human breast tissues were unable to 
demonstrate the presence of any of the cPLA2 isozyme proteins. The results of this research 
indicate that the tumorigenic human breast cell lines MDA-MB 231 and MCF-7 express the 
cPLA2α, cPLA2β and cPLA2γ proteins, and that the cPLA2 proteins could not be detected in 
the non-tumorigenic human breast cell line, MCF-10A. The A23187 elicited redistribution of 
cPLA2α and cPLA2β proteins within the cells, and decreased signal in AACOCF3 pretreated 
specimens provides evidence supporting antisera specificity.  Although cPLA2α is recognized 
to be the principal enzyme responsible for AA release leading to eicosanoid biosynthesis, 
cPLA2β and cPLA2γ, which share ~30% homology with cPLA2α, may also participate in 
releasing AA and could support pro-inflammatory eicosanoid biosynthesis.  Further 
investigations will be necessary to fully define the regulation of the cPLA2 isozymes in the 
MDA-MB 231 and MCF-7 cells.  The expression of the cPLA2 isozymes in cancerous human 
breast tissue remains undescribed. 
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viii 
 
PDGF              Platelet-derived growth factor 
ROS  Reactive oxygen species 
SDS                 Sodium dodecyl sulfate 
TBST              Tris buffered saline Tween-20 
TNFα              Tumor necrosis factor α 
TGFβ              Transforming growth factor β 
 
 
  
1 
 
INTRODUCTION  
2 
 
Breast cancer is one of the most widespread cancers among women worldwide.  In 
the US, it is the most common cancer, and the leading cause of cancer-related deaths, among 
women between 45-64 years of age (Ward et al., 2008, American Cancer Society, 2010).  
Early detection and improved treatment procedures have resulted in a gradual decline in the 
number of deaths caused by the disease since 1990 (Ward et al., 2008, American Cancer 
Society, 2010).  Nevertheless, in 2010, the estimated death toll in the USA for the disease 
was 39,840 (American Cancer Society, 2010).  The gravity of the disease, therefore, demands 
further research focused on its early diagnosis, its treatment, and for evaluating the prognosis 
of the disease course.  
Breast cancer is a heterogeneous disease characterized by a complex interplay of 
molecular, genetic, and physiological factors.  The identification of some common 
characteristics, such as c-erb-b2/her-2/neu oncogene expression (Jimenez et al., 2000; 
Kallioniemi et al., 1991), mutations in the BRCA-1 (Miki et al., 1994; Welcsh et al., 2002), 
or BRCA-2 genes (Venkitaraman, 2002), as well as assays of the tumor ER/PR status (Ferno 
et al., 1990; Warnberg et al., 2001; Xu et al., 2003) have provided approaches for possible 
intervention.  However, the totality of the molecular factors that contribute to the onset and 
progression of breast cancer remains undefined.  Continuing investigations are expected to 
identify additional molecular pathways involved in the onset and progression of the disease, 
and to guide the exploration of novel therapeutic approaches.   
Numerous reports (Coussens and Werb, 2002; Kim et al., 2009; Mantovani et al., 
2008) indicate that inflammation may be associated with the onset and progression of many 
cancers, including cancers of the breast.  Metastatic potential is also linked with an 
inflammatory environment (Kim et al., 2009).  A mechanism contributing to an inflammatory 
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state is the arachidonic acid (AA) cascade producing the eicosanoids, a group of bioactive 
lipids that are often pro-inflammatory.   
There have been numerous reports linking AA and the eicosanoids to cancer biology 
(Markaverich et al., 2007; Nie et al., 2001; Pan et al., 2008; Sveinbjornsson et al., 2008).  AA 
is typically esterified in the membrane glycerophospholipids, and in that state the fatty acid is 
not useful to the eicosanoid synthesizing pathways.  However, AA can be released from the 
glycerophospholipids by enzymes of the phospholipase A2 (PLA2) family, and the free AA 
can be converted into the eicosanoids.  Enzymatic utilization of AA by the cyclooxygenases 
(COXs) and the lipoxygenases (LOXs) are chiefly responsible for initiating the synthesis of 
the eicosanoids from free AA.  Elevated levels of COX-2 have been identified in archived 
breast cancer tissues, and studies indicate that COX-2 overexpression is sufficient to induce 
mammary tumor formation in transgenic mice (Denkert et al., 2004; Liu et al., 2001).  
Cancerous human breast tissues reveal a 3- to 30- fold higher level of 12-LOX mRNA when 
compared to paired normal breast tissue (Ding et al., 2003; Natarajan et al., 1997).  The 
linkage of the COX and LOX enzymes with cancer has been frequently studied, but fewer 
investigations have focused on the enzyme cytosolic phospholipase A2 (cPLA2), the PLA2 
principally responsible for releasing AA necessary for eicosanoid synthesis (Fujishima et al., 
1999; Six and Dennis, 2000).  AA release is the obligate first step in the biosynthesis of 
eicosanoids.  
The PLA2’s are a family of esterases that catalyze the hydrolysis of the sn-2 bond of 
cellular glycerophospholipids.  AA is frequently found esterified at the sn-2 position.  Of the 
five PLA2 categories (reviewed below), the cPLA2 group is principally responsible for the 
initial release of AA in response to cell-stimulation by proinflammatory cytokines and 
4 
 
hormones.  In the 1990’s, it was determined that cPLA2 consisted of several related proteins, 
designated as cPLA2α, cPLA2β and cPLA2γ.  Additional enzymes have since been identified 
(Schaloske and Dennis, 2006), but only cPLA2α, cPLA2β and cPLA2γ will be considered 
further in this report.  Expressed sequence tag (EST) analyses using cPLA2α sequences 
identified the β and γ isoforms of cPLA2.  We hypothesize that the cPLA2 isozymes α, β and 
γ play significant, though possibly distinct roles in breast cancer by contributing to AA 
release and, thereby, to eicosanoid generation.  Furthermore, distinctive variations in the 
levels in one or all of the isozymes in normal and transformed breast cancer cells may exist 
and this may be significant in terms of assessing breast cancer risk, onset, progression, 
proclivity to metastasize, and patient prognosis.  Preliminary results from this laboratory 
(Maricica Pacurari, 2006) demonstrated cPLA2β and cPLA2γ mRNA expression in the 
human breast cancer cell line MCF-7 by real time RT-PCR assays.  However those 
experiments left it uncertain if cPLA2α mRNA was also expressed in those cells, and the 
expression of the encoded proteins was only addressed in those studies, in a preliminary 
manner.   
In those studies an antisera specific to cPLA2β and cPLA2γ were generated using 
gene specific antigenic amino acid sequences corresponding to the respective cPLA2 
isoforms.  The present studies were undertaken to produce a cPLA2α antiserum and to 
determine if the cPLA2 isozymes, -α, -β and -γ, were expressed in the breast cancer cell lines 
MDA-MB-231 and MCF-7, and in the immortalized non-tumorigenic human breast cell line 
MCF-10A.  Additionally, surgically removed cancerous human breast tissues were to be 
screened for cPLA2 isozyme expression.  
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BACKGROUND  
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 Cancer is characterized by several distinct features including uncontrolled cell 
division, resistance to growth inhibitors, evasion of apoptosis, invasion of distant tissues, the 
ability to induce angiogenesis, and immortality (reviewed in Hanahan and Weinberg, 2000).  
The recognition and evaluation of oncogenes with a dominant gain of function and the tumor 
suppressor genes with a recessive loss of function has provided valuable information on the 
emergence and progression of the disease (Bishop and Weinberg, 1996).   
 Breast cancer represents one of the most common cancers among women in the US, 
representing approximately 1 in 4 cancers diagnosed.  The American Cancer Society (2010) 
has classified breast cancer as in situ when it is localized in the ducts or in the lobules of the 
breast and invasive when the disease has spread out of the ducts of the glandular walls 
thereby invading the surrounding tissue.  It was estimated that there will be 207,090 new 
cases of invasive breast cancer and an additional 54,010 new cases of in situ breast cancer in 
2010.  Assignment of stages in breast cancer depends on tumor size and the extent of its 
spread through the breast tissue and the neighboring organs (T), as well as the involvement of 
the lymph node (N) and presence or absence of distant metastases (M).  The assigned stages 
are I, II, III and IV, where Stage I represents the early disease and Stage IV the highly 
advanced disease (American Cancer Society, 2010).  Displaying a complex interplay of 
molecular, genetic and physiological factors, breast cancer is a heterogeneous group of 
diseases, presenting major challenges to physicians and scientists.  Individuals with inherited 
mutations of the breast cancer susceptibility genes, BRCA1 and BRCA2 have a high risk of 
developing the disease and these mutations are estimated to be responsible for 5%-10% of 
breast cancer incidence (American Cancer Society, 2010).  BRCA1 and BRCA2 are tumor 
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suppressor genes involved in transcriptional regulation and DNA damage repair (Welcsh and 
King, 2001).  
 Studies on animal and human cancer cells have revealed that tumorigenesis is a 
multistep process, and that each step correlates with genetic alterations that lead to the 
progressive transformation of normal human cells into highly metastatic derivatives (Bishop 
and Weinberg, 1996).  An active proliferative state in normal cells is initiated by mitogenic 
growth signals and their processing by subsequent downstream cytoplasmic counterparts.  
Most of the growth signals are synthesized by one cell type to stimulate the proliferation of 
another, a process known as heterotypic signaling.  However, many cancer cells acquire the 
ability to generate or activate their own growth signals, thereby becoming independent of 
stimulation from exogenous mitogenic stimuli (Fedi et al., 1997).  Examples of self-
stimulation are the platelet-derived growth factor (PDGF) and transforming growth factor 
(TGF)-α production by glioblastomas and sarcomas (Fedi et al., 1997).  Moreover cell 
surface receptors responsible for the transmission of the growth stimulatory signals into the 
cell interior may also be dysregulated in cancers.  The epidermal growth factor receptors 
(EGF-R/erbB) are upregulated in some stomach, brain and breast tumors, and the HER2/neu 
receptor is often overexpressed in stomach and breast cancers (Yarden and Ullrich, 1988).  
Cancer is sometimes characterized by ligand independent signaling through the structural 
alteration of receptors.  Truncation of the major part of the cytoplasmic domain of EGF 
receptor has been shown to constitutively transmit signals (Fedi et al., 1997) leading to 
metastasis.  
The intricate signaling networks that drive normal cell division and restrict cellular 
proliferation are thus altered and utilized in cancer cells promoting uncontrolled replication 
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and survival.  Mitogenic signals are transmitted to the interior of the cell by a series of 
distinct and often crosstalking signaling pathways.  The acquisition of growth factor 
autonomy can be achieved by the accumulation of alterations in the downstream members of 
the cytoplasmic network that receive and process the signals transmitted by the growth factor 
receptors.  The following section comprises a review of some of the principal signaling 
networks operating in cancers.  This content is provided as a frame of reference for 
transformation and metastasis because the various eicosanoids can mediate similar responses 
and effects to those described for the polypeptides discussed.   
 
SIGNALING PATHWAYS AND CANCER: 
Ras-Mitogen Activated Protein Kinase (MAPK) Pathway: 
The Ras-MAPK pathway plays a significant role in regulating normal cell division 
and malignant transformation.  The activation of receptor tyrosine kinases (RTKs) by growth 
factors leads to the occupancy of Ras by GTP as mediated by Son of Sevenless (SOS).  The 
GTP-bound Ras is the active form of Ras.  Neurofibromin 1 (NF1) is a negative regulator of 
Ras activation by GTP.  Activated Ras activates the serine/threonine kinase Raf that, in turn, 
phosphorylates and activates a MAPK/ ERK kinase (MEK), which then leads to the 
activation of ERK.  ERK 1/2, upon translocation to the nucleus, leads to the activation of the 
AP1 transcription factors.  The stimulation of these transcriptional regulators causes the 
expression of the D-type cyclins enabling the cell to progress through the G1 phase of the 
cell cycle and enter S-phase.  Several human tumors exhibit activating mutations in the Ras 
genes (Bos, 1989).  Most of these mutations result in constitutive pathway activation leading 
to hyperproliferation.  Ras pathways have also been implicated in the induction of angiogenic 
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factors and ERK-mediated expression of matrix metalloproteinases (MMPs) (reviewed in 
Downward, 2003).  The MMPs are capable of degrading all components of the extracellular 
matrix and are therefore associated with several aspects of tumor metastasis such as 
malignant tumor growth, tumor-induced angiogenesis and tumor invasion (Vihinen and 
Kahari, 2002).  45% of colon cancers and 90% of pancreatic cancers exhibit Ras mutations 
(Katz et al., 2007).  The Ras-MAPK signaling cascade cross-talks with other pathways, and 
thereby enables the Ras activating signals to have multiple biological effects.   
 
Phosphatidylinositol 3- kinase (PI3K) Pathway:  
 The PI3K cascade can be activated by Ras and also by the RTKs.  PI3K 
phosphorylates phosphatidylinositol-4, 5-bisphosphate (PIP2), to produce 
phosphatidylinositol-3, 4, 5-triphosphate (PIP3).  PIP3 leads to the activation of several 
downstream signaling pathways.  One principal downstream mediator of PIP3 is AKT, a 
serine/threonine kinase.  Activated PI3K/AKT signaling is associated with cellular energy 
metabolism, cell proliferation, and survival (reviewed in Dreesen and Brivanlou, 2007).  p53, 
a transcription factor heavily involved in DNA damage surveillance, can be negatively 
regulated by AKT through the activation of MDM2 by AKT dependent phosphorylation.  
The tumor-suppressor PTEN opposes the PI3K/AKT pathway by dephosphorylating PIP3.  
PTEN mutations have been implicated in glioblastomas, lung carcinomas, and melanomas 
(Vivanco and Sawyers, 2002).  AKT overexpression has been found in breast, ovarian and 
thyroid cancers (Vivanco and Sawyers, 2002).  Activated AKT can directly and indirectly 
inhibit the pro-apoptotic mediators BAD and pro-caspase 9.   
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Janus Kinases (JAK)/ Signal Transducers and Activators of Transcription (STAT) 
Pathways: 
In response to certain growth factors and cytokines, the JAK/STAT signaling 
pathways stimulate cellular proliferation, differentiation, migration, and apoptosis (Rawlings 
et al., 2004).  A wide array of ligands stimulate JAK, a soluble tyrosine kinase that acts on 
STAT and other substrates.  Phosphorylated STATs enter the nucleus and bind to specific 
regulatory DNA-sequences to activate or repress transcription of target genes.  STAT can 
also be activated by the EGF or PDGF (Darnell, 2002).  Mutations of the JAK/STAT 
signaling components, such as HER2/neu (breast and stomach cancers) and EGF-R (breast, 
brain and stomach cancers), can lead to hypersensitivity towards mitogenic signals and, 
thereby, promote proliferation (Slamon et al., 1987; Yarden and Ullrich, 1988).   
 
Notch signaling pathway:  
The Notch signaling pathway is associated with several cell fate specification events 
and is associated with many developmental defects and cancer.  Notch can inhibit cellular 
differentiation due to lateral inhibition, or can promote adjacent cells to adopt the same cell 
fate by lateral induction (Ehebauer et al., 2006).  Binding of Notch ligands such as Delta, 
Serrate or Lag2 to their cognate Notch receptor leads to the cleavage of the intracellular 
domain of Notch (NICD).  NICD translocates to the nucleus and forms a transcriptional 
activation complex with the DNA- binding factors CSL (Suppressor of Hairless), and the 
Mastermind like protein family (MAML), causing the activation of the Hairy Enhancer of 
Split (HES) family.  Aberrant Notch signaling has been implicated in breast tumors, 
melanoma progression, medullablastoma, and ovarian cancers (Roy et al., 2007).  The 
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presence of ligands such as Jagged I and the amplification of Notch receptors have been 
shown to be involved with an aggressive form of breast cancer (reviewed in Dreesen and 
Brivanlou, 2007).  It has been proposed that Notch signals possibly increase cell proliferation 
by the activation of a downstream target, the transcription factor c-myc.  Deregulated c-myc 
expression is evident in many cancers.  
 
Transforming growth factor (TGF)-β: 
 TGF-β is a ubiquitously expressed cytokine that plays significant roles in cellular 
functions such as cell cycle arrest, apoptosis, homeostasis, immune regulation, and wound 
healing (Bierie and Moses, 2006b; Massague, 2008).  Although TGF-β is a tumor suppressor, 
there is ample evidence that it acts as a pro-metastatic cytokine in advanced stage tumors 
(reviewed in Dreesen and Brivanlou, 2007).  The activation of the TGF-β mediated pathways 
involves binding of TGF-β to the extracellular domain of the Type I and Type II TGF-β 
receptors.  This leads to the phosphorylation and activation of the latent cytoplasmic 
transcription factors, the SMADs.  The phosphorylated SMADs (1, 2, 3, and 5) form a 
complex with SMAD 4, thereby eliciting its translocation to the nucleus where it regulates 
the transcription of target genes.  These include down-regulating c-Myc and the Id family of 
transcription factors, and upregulating p15
INK4b
 and p21
CIP2,8
 expression.  The latter proteins 
inhibit cell cycle progression.  Decreased expression of the SMAD proteins, as well as 
mutations of the TGF-β receptors, have been reported in a number of human cancers 
including pancreatic, colorectal, and gastric cancers, thereby supporting the role of TGF-β as 
a tumor suppressor (Derynck et al., 2001; Massague, 1998, 2008).  However, breast cancers, 
melanomas and prostate cancers display active TGF-β signaling (Siegel and Massague, 
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2003).  In the highly metastatic breast cancer cell line MDA-MB 231, transcriptional 
repression of c-Myc and Id genes by TGF-β is selectively inactivated (Chen et al., 2001).  
This supports the continuous growth of these tumor cells, even in the presence of high levels 
of TGF-β.  TGF-β can augment epithelial tumor malignancy by promoting epithelial-
mesenchymal cell transition (EMT), an effect that enhances migration and invasion in tumor 
cells, a process resembling the highly coordinated cellular movements that happen during 
embryogenic development (Oft et al., 1996).   
 
Nuclear factor-kappa (NF-κ)B: 
 NF-κB is a transcription factor that plays significant roles in proliferation, stress 
response, innate immunity, and inflammation (Courtois and Gilmore, 2006; Ghosh et al., 
1998).  Studies indicate that NF-κB plays an important role in cancer development (reviewed 
in Grivennikov et al., 2010).  NF-κB is activated by a wide range of extracellular factors 
including tumor necrosis factor-α (TNFα), interleukin-1, some growth factors, bacterial or 
viral infections, and oxidative stress.  In the absence of stimulation, inactive NF-κB dimers 
are located in the cytoplasm.  The inactive state of the NF-κB dimers is caused by its 
interaction with the I-κB inhibitory proteins.  In response to stimuli, the I-κB proteins are 
rapidly phosphorylated by I-κB kinase (IKK), which elicits its release from the complex with 
the NF-κB dimers.  The free NF-κB can translocate to the nucleus and activate transcription 
of several target genes, including cyclin D1, c-myc, and c-myb, thereby demonstrating that 
NF-κB can act as a positive regulator of cell cycle progression.  Activated NF-κB can oppose 
apoptosis by increasing transcription of anti-apoptotic members of the Bcl-2 family and 
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cIAPs  (Karin et al., 2006).  NF-κB driven responses inhibit p53-induced apoptosis 
(Tergaonkar et al., 2002).   
NF-κB is also associated with several aspects of invasive cell growth and survival.  
Its activity leads to increased angiogenesis by the upregulated expression of vascular 
endothelial growth factor (VEGF) (Li et al., 2002), COX-2, and inducible Nitric Oxide 
synthase (iNOS) (Greten and Karin, 2004).  It promotes invasive growth by elevating the 
expression of the matrix metalloproteinases (MMP), plasminogen activator, and heparanase 
(Andela et al., 2000; Bond et al., 1999).  NF-κB also regulates the effects of several 
chemokines, thus promoting cell migration (Johnson, 1999).  The activation of NF-κB during 
chronic inflammation and its constitutive expression in some cancers suggests a significant 
role played by NF-κB in the initiation and promotion of cancer.  NF-κB can contribute to the 
production of reactive oxygen species (ROS) in macrophages and neutrophils through the 
induction of the production of iNOS and other enzymes (Forman and Torres, 2001).  The 
ROS produced can diffuse internally and enter the surrounding cells and cause DNA damage 
(Karin et al., 2002).  Elevated expression of NF-κB during chronic inflammation can prevent 
the elimination of genetically altered cells by inhibiting apoptosis.  The human REL gene, 
which encodes one of the five NF-κB transcription factor family members, is amplified in 
Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma (reviewed in Dreesen and Brivanlou, 
2007).  
 Cancers in general exhibit characteristics such as uncontrolled cell division, 
resistance to growth inhibitors, evasion of apoptosis, invasion of distant tissues, the ability to 
induce angiogenesis, and immortality; however, cancerous tissues can differ widely in the 
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paths taken to acquire the malignant phenotype.  Within a given cancer type, mutation of 
particular target genes may be found in only a subset of histologically identical tumors.   
 
INFLAMMATION AND CANCER: 
Rudolf Virchow, in the year 1863, proposed that cancer originates at sites of chronic 
inflammation.  Cell proliferation and inflammation are normal characteristics of wound 
healing.  In a normal tissue, wound healing is accomplished through the production of pro-
inflammatory cytokines but they are closely followed by the anti-inflammatory cytokines, 
and normal inflammation is self-limiting (reviewed in Coussens and Werb, 2002).  
Proliferating cells undergo and sustain mutagenic assaults in the proinflammatory 
microenvironment.  Their continued survival may be due to the persistent presence of the 
proinflammatory mediators, which is sensitive to the failure of factors required to resolve the 
inflammatory response (Dvorak, 1986).  
 Inflammatory conditions can by themselves elevate cancer risk, as is evident in 
inflammatory bowel disease.  However, genetic alterations in a tissue can also lead to 
inflammation and neoplasia (Mantovani et al., 2008).  Persistent infections can induce 
chronic inflammation.  Leukocytes and other phagocytic cells produced to fight such 
infections cause DNA damage in proliferating cells through the generation of reactive 
oxygen and nitrogen species.  These products react to form peroxynitrite, a mutagenic agent.  
Repeated tissue damage and its subsequent regeneration can lead to permanent genetic 
alterations such as point mutations, deletions or rearrangements (Maeda and Akaike, 1998).  
DNA damage resulting from chronic inflammation caused by infections by Helicobacter 
pylori is the world’s leading cause of stomach cancer (Ernst and Gold, 2000).   
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 Pro-tumorigenic actions of the inflammatory cells include the release of several 
growth and survival factors, the promotion of angiogenesis and lymphangiogenesis, causing 
DNA damage, the remodeling of the extracellular matrix (ECM), thereby facilitating 
invasion (reviewed in Coussens and Werb, 2002).  A developing tumor microenvironment 
comprises a diverse array of leukocytes such as neutrophils, dendritic cells, macrophages, 
eosinophils, mast cells and lymphocytes, all of which can lead to the production of cytokines, 
ROS, MMP, TNFα, interleukins (ILs), and interferons (IFs) (Kuper et al., 2000; Wahl and 
Kleinman, 1998).  Infiltrating macrophages in breast cancer can lead to TNFα production, 
which may regulate thymidine phosphorylase, an angiogenic enzyme (Leek et al., 1998).  
Neoplastic tissue infiltrates indicate the presence of tumor associated macrophages (TAMs), 
COXs (responsible for the production of the prostaglandins, leukotrienes and thromboxanes), 
chemokines, and dendritic cells (reviewed in Balkwill and Mantovani, 2001).  The TAMs 
play a dual role of killing neoplastic cells upon activation by IL-2, IF, and IL-12 and 
producing angiogenic and lymphangiogenic growth factors, cytokines and proteases which 
can lead to tumor progression (Mantovani et al., 1992).   
 Members of the Ras-Raf signaling pathway are frequently mutated in cancers and can 
lead to the production of tumor promoting chemokines and cytokines (Guerra et al., 2007; 
Sparmann and Bar-Sagi, 2004; Sumimoto et al., 2006).  Deregulated expression of the 
transcription factor Myc can favor the remodeling of the tumor microenvironment through 
the recruitment of inflammatory mediators.  Tumor suppressor proteins such as TGF-β and 
PTEN can also regulate the production of inflammatory mediators (Balkwill, 2004; Bierie 
and Moses, 2006a; Phillips et al., 2005).   The transcription factor NF-κB can be activated 
during genetic alterations and can regulate the activity of genes encoding inflammatory 
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cytokines, adhesion molecules, COX-2, NOS, and various angiogenic factors.  NF-κB can 
promote cell survival by inducing the expression of anti-apoptotic genes (Bcl-2) and 
inhibiting p53 induced apoptosis (Karin et al., 2006).  NF-κB is involved in the initiation and 
progression of cancers of the GI-tract and liver (Greten et al., 2004; Pikarsky et al., 2004).  
The STAT3 transcription factor is also associated with oncogenesis by remaining 
constitutively activated in immune and tumor cells.  STAT3 is also involved with the 
inhibition of apoptosis (Bromberg et al., 1999).  The multiple signaling pathways disrupted in 
cancer can provide an ambient environment for tumor growth by promoting inflammation.  
 A critical mechanism leading to pain and inflammation is the arachidonic acid (AA) 
pathway.  AA serves as the precursor of the group of bioactive lipids collectively known as 
the eisosanoids.  The eicosanoids include the prostaglandins (PGs), thromboxanes (Txs), 
hydroxyeicosatetraenoic fatty acids (HETEs), leukotrienes (LTs), and the lipoxins (Brash, 
1999; Smith et al., 2000).  There have been several reports that AA and its products, the 
eicosanoids, are intimately linked to cancer biology.  Some cancer cells depend on the 
overexpression of the AA metabolizing enzymes, the COXs and the LOXs for survival (Gao 
et al., 1995).  Inhibitors of these enzymes have antineoplastic characteristics (Wong et al., 
2001).    
 
EICOSANOIDS: 
The eicosanoids are potent lipid mediators that can act in the nanomolar range 
(reviewed in Funk, 2001).  The COX, LOX and the cytochrome P450 monooxygenase 
pathways are responsible for the commitive steps in eicosanoid generation, but can aberrantly 
metabolize AA during chronic inflammation and carcinogenesis.  The eicosanoids regulate 
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numerous physiological processes including multiple aspects of inflammation.  Common 
diseases like arthritis, ischemic cardiovascular disease, and asthma display an inflammatory 
role of the eicosanoids (Serhan, 2005).  The eicosanoids have also been implicated as 
mediators of cell proliferation, transformation, angiogenesis, cancer progression, and 
metastasis (Choy and Milas, 2003), in various tissues, including cancers of the mammary 
gland.  The biosynthesis of the eicosanoids is rate-limited, partly, by the availability of free 
AA.   Esterified AA is typically not a substrate for the COX, LOX or P450 enzymes, thus, 
AA release, must precede AA’s subsequent metabolism by the eicosanoid producing 
enzymes from the glycerophospholipids by a phospholipase.   
The prostanoids, specifically the prostaglandins (PGs), exert their biological effects 
through their cognate cell surface receptors.  These belong to the G protein-coupled receptor 
(GPCR) family.  Recent studies indicate that certain PGs can activate nuclear receptors of the 
peroxisome proliferator-activated receptor (PPAR) family.  The expression of the cognate 
receptors varies in a cell type specific manner, and this determines the specific action of the 
different PGs in that particular tissue.  The prostanoids are synthesized in most tissues, and 
they commonly function in an autocrine or paracrine manner.   
          Among the PGs, PGE2 is the most abundant and is produced by different human 
cancers, including colon, lung and breast.  Murine models of colorectal cancer have shown 
that PGE2 is necessary for tumor growth (Park et al., 2007; Wang et al., 2004).  PGE2 
promotes tumor growth in small and large intestinal adenoma as indicated by studies in 
Apc
Min/+
 mice.  The usage of a PG receptor antagonist has been shown to reduce chemically 
induced breast cancer development in mice (Kawamori et al., 2001).   
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The 5-LOX enzyme converts AA to the unstable LTA4 through the intermediate 
product 5-HPETE.  LTA4 is converted into 5-HETE, or is hydrolysed into LTB4.  In some 
tissues 5-HPETE is converted into the cysteinyl leukotriene, LTC4, by the addition of the 
tripeptide glutathione.  LTB4 is upregulated in some human colon and prostate cancers (Larre 
et al., 2008).  Inhibiting LTB4 synthesis by treatment with LTA4 hydrolase inhibitor, bestatin, 
reduced tumor incidence in murine models of esophageal adenocarcinoma (Chen et al., 
2003).    
Numerous animal studies, clinical trials and population studies have revealed the 
significance of the prostanoid and leukotriene biosynthetic pathways in cancer (reviewed in 
Greenhough et al., 2009).  The eicosanoids operate through different mechanisms that can 
modulate tumor initiation and progression.  Eicosanoids regulate cell proliferation by 
activating the receptors on tumor epithelial cells; they can induce the secretion of growth 
factors and angiogenic factors.  They can regulate apoptosis, migration and invasion, thus 
comprehensively causing a shift of the normal cellular environment into a tumor supporting 
one (reviewed in Wang and Dubois, 2010).    
 
ARACHIDONIC ACID (AA):   
Arachidonic acid is an essential polyunsaturated fatty acid (20:4, n-6), typically found 
esterified at the sn-2 position of cellular glycerophospholipids (Chen et al., 2008b; Irvine, 
1982).  As stated, it serves as the precursor for the bioactive lipids known as the eisosanoids.  
Each of these metabolites is formed by the enzymatic mono- or bis-oxygenation of AA, or, 
rarely, of dihomo-γ-linolenic acid or eicosapentaenoic acid.  Three different groups of 
enzymes primarily utilize free AA as a substrate leading to bioactive lipid synthesis.  They 
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include the cyclooxygenases (COXs), the lipoxygenases (LOs) and the cytochrome P450 
monooxygenases.  The esterified form of AA is not a substrate for most eicosanoid 
producing enzymes, thus, the release of AA must precede its subsequent metabolism by the 
COXs and the LOX’s.   
  In the recent years, studies on bioactive lipid regulation have gained prominence.  In 
unstimulated cells, free AA is held at low concentrations, thereby limiting the basal rate of 
eicosanoid production (Fitzpatrick and Soberman, 2001).  Hence, the availability of AA 
serves as the rate limiting factor in eicosanoid generation.  The mobilization of AA from the 
cellular membrane glycerophospholipids is accomplished by esterases of the phospholipase 
A2 (PLA2) family (Kudo and Murakami, 2002).  PLA2 is activated in response to a variety of 
stimuli including the cytokines, growth factors, hormones or even simple mechanical 
stimulation.  Because free AA can be reincorporated into cellular lipids by acyltransferase 
and transacylase reactions (Snyder et al., 1992), eicosanoid production is a function of a 
competition between the acylation/reacylation pathways, and the enzymes leading to 
eicosanoid synthesis.   
 
CYCLOOXYGENASES (COX): 
The COX enzymes, COX-1 and COX-2, catalyze the dioxygenation of AA.  This 
leads initially to PGG2 endoperoxide production.  This is then reduced by COX’s peroxidase 
activity into PGH2 endoperoxide.  PGH2 can then be used by isomerases, reductases, or 
synthetases, to produce the PGs (PGD2, PGE2, and PGF2), prostacyclin, or TX.  Of the COX 
enzymes, COX-1 is constitutively expressed in tissues and contributes to tissue homeostasis.  
COX-2, whose expression is inducible, is principally associated with the regulation of 
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inflammation.  There is evidence that COX-2 plays vital roles in cancerous tissues of the 
breast, colon and the pancreas (Lupulescu, 1978; Muller-Decker and Furstenberger, 2007).  
Carcinogenesis can be induced in cultured mouse fibrosarcoma cells by increasing the 
amount of the available PGs.  There is evidence that the usage of COX-2 inhibitors can 
reduce cell growth in cancers of the skin, colon, esophagus, gall bladder, pancreas, and breast 
(Barry et al., 2009; Chen et al., 2004; Fegn and Wang, 2009; Ye et al., 2005).  Increased 
expression of COX-2 has been observed in adenomas and adenocarcinomas of the colon 
(Eberhart et al., 1994).  
Cyclooxygenases and Breast Cancer:  An elevated level of the PGs in breast tumors, with 
even further higher levels in the metastatic disease, was the first evidence of the involvement 
of COX-2 in the disease (Bennett et al., 1977; Rolland et al., 1980).  Mammary tumors are 
sensitive to treatment by both specific and non-specific COX-2 inhibitors (Schreinemachers 
and Everson, 1994).  Studies on transgenic mice have indicated that the overexpression of the 
COX-2 enzyme is sufficient to induce mammary tumor formation (Liu et al., 2001).  These 
tumors were sensitive to treatment by COX-2 inhibitors.  A decline in the levels of COX-2 
and PGs in mice led to an elevation of the incidence of apoptosis in tumorous tissues 
indicating an inverse relationship of PGs to apoptosis (Liu et al., 2001).   
 
LIPOXYGENASES (LOX):  
The LOXs are a family of dioxygenases whose products have been described to be 
involved in processes like cell differentiation, inflammation, and cancer (Brash, 2001).  The 
LOXs are placed into different classes based on their positional specificity of AA 
oxygenation.  The principal members of the LOX family include the 5-, 12- and 15- LOXs.  
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LOX products such as 5- and 12-HETE and the leukotrienes (LT) appear to mediate 
proliferative, adhesive, and metastatic properties in tumor cells (reviewed in DuBois, 2003).  
5- and 12-HETE have also been shown to modulate apoptosis, and studies have indicated that 
the inhibition of 5- and 12-LOX causes an elevation in apoptosis in various tumor models 
displayed by responses in bcl-2 and bax expression (Chen et al., 2008a; Vincent et al., 2008).  
12-HETE plays a crucial role in modulating several steps during metastasis and cancer cell 
adhesion.  12-HETE can stimulate PKC activity (Liu et al., 1991), which can cause the 
release of the cysteine protease cathepsin B; cathepsin B is involved in tumor metastasis and 
invasion (Honn et al., 1994).  The LT’s, LTA3 and LTA4, are also produced in inflammatory 
cells such as the polymorphonuclear leukocytes, macrophages, and mast cells (reviewed in 
Funk, 2001).  Solid tumors of the human breast, prostate, colon, and the human breast cancer 
cell line MCF-7, display elevated levels of 12-LOX mRNA (Endsley et al., 2007; Natarajan 
et al., 1997; Natarajan and Nadler, 1998; Steele et al., 1999).  LOX inhibitors have been 
shown to prevent rat mammary gland cancers and carcinogen-induced lung adenomas 
(Matsunaga et al., 1998; Moody et al., 1998; Rioux and Castonguay, 1998).  
Lipoxygenases and Breast Cancer: Human cancerous breast tissues display a 3- to 30-fold 
higher 12-LOX mRNA level compared to normal breast tissue (Ding et al., 2003; Natarajan 
et al., 1997).   12-LOX expression is elevated in the breast cancer cell lines MCF-7, MDA-
MD 231, COH-Br1, and T47D (Natarajan and Nadler, 1998).  The same study also identified 
an increase in 12-LOX expression in the MCF-7 cell line after treatment with EGF.  12-LOX 
expression has also been shown to be elevated in breast cancer tissues (Natarajan et al., 
1997).  The use of LOX inhibitors inhibited the proliferation of MCF-7 cells (Natarajan and 
Nadler, 1998).    
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PHOSPHOLIPASES (PLA2): 
The phospholipases A2 are a family of esterases that catalyze the hydrolysis of the sn-
2 bond of cellular glycerophospholipids, leading to the release of arachidonic acid.  PLA2 
catalysis yields lysophospholipids, which can serve as lipid mediators (Murakami and Kudo, 
2002; Six and Dennis, 2000).  The PLA2s play significant roles in the maintenance and 
turnover of membrane phospholipids, signaling, tissue repair, and in the inflammatory 
response (Dong and Matsumura, 2008; Jurivich et al., 1996; Murakami and Kudo, 2002; Six 
and Dennis, 2000).  However, certain members of the phospholipase family have been 
implicated specifically in inflammation and tissue repair, thereby raising the possibility of a 
pathological role.  There are reports that the expression of PLA2 is elevated upon treating 
cells with pro-inflammatory cytokines and growth factors (Capper and Marshall, 2001).  
A diverse array of PLA2 enzymes are found in mammalian tissues, each with a 
distinct mechanism of regulation.  These enzymes have been classified into 19 forms 
(Schaloske and Dennis, 2006; Six and Dennis, 2000), based on gene nucleotide sequences, 
and have been characterized, purified and cloned.  The PLA2 superfamily is divided into 5 
families of enzymes (Schaloske and Dennis, 2006), including the secretory PLA2 (sPLA2), 
cytosolic PLA2 (cPLA2), the Ca
2+
-independent PLA2 (iPLA2), the platelet-activating factor 
acetylhydrolases (PAF-AH), and the lysosomal PLA2’s.   
 
SecretoryPLA2 (sPLA2): 
The sPLA2 family includes 17 different members, and these require the presence of 
µM Ca
2+
 for catalysis.  They have a conserved catalytic site and display 5 to 8 disulfide 
bonds (Schaloske and Dennis, 2006).  Some of the sPLA2 enzymes are involved with 
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releasing AA from the intracellular membranes, while others operate on the outer surface of 
the plasma membrane.  sPLA2’s play vital roles in inflammatory diseases and have been 
shown to be present at high concentrations in patients suffering from rheumatoid arthritis, 
inflammatory bowel disease, and pancreatitis, among others (Bidgood et al., 2000; Schaloske 
and Dennis, 2006).  sPLA2’s are also elevated in prostate cancers (Sved et al., 2004) and in 
colorectal adenocarcinomas (Mounier et al., 2008). 
 
Cytosolic PLA2 (cPLA2): 
A second family of the PLA2’s, the cPLA2 enzymes, includes 6 members, which are 
grouped by virtue of sequence homologies. These display a conserved catalytic site that 
includes a conserved serine residue and requires μM Ca2+ for function (Kim et al., 1991).   
cPLA2 will be discussed extensively in a subsequent section.  
 
Ca
2+
-independent PLA2 (iPLA2): 
 The iPLA2 family functions in the release of AA from the membrane 
glycerophospholipids in unstimulated cells and do not require Ca
2+
 for their activity.  There 
are 7 identified members in the iPLA2 family, which are similar to cPLA2 in that they utilize 
a catalytic serine for catalysis.  The rate of AA release due to iPLA2 activity does not exceed 
the rate at which AA is reincorporated into membrane lipids and, hence, appears to be 
unconnected with eicosanoid biosynthesis.  However, activation of iPLA2 during cardiac 
ischemia has been reported to lead to lethal ventricular tachyarrythmias (Mancuso et al., 
2003).   
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Platelet-activating factor acetylhydrolases (PAF-AH): 
The PAF-AH family consists of 2 groups of serine PLA2’s that hydrolyze an acetyl 
group from the sn-2 position of the PAF precursors, a group of phosphotidylcholine based 
glycerophospholipids in which the sn-1 chain is linked by an ether linkage and the sn-2 
position is occupied by an acetyl group (Six and Dennis, 2000).  The PAF-AH family 
consists of 4 members ranging in size from 26-45 kDa.  PAFs exhibit numerous pro-
inflammatory properties, such as eliciting platelet aggregation, stimulating the production of 
ROS, and increasing LT biosynthesis (Izaki et al., 1996).  The hydrolysis of the sn-2 acetyl 
group abolishes the pro-inflammatory effects of PAFs (Peplow, 1999).   
Two distinct pathways, the de novo and the remodeling pathways, have been 
identified for the biosynthesis of PAF.   In the latter pathway, cPLA2 is involved in PAF 
biosynthesis, and its actions closely parallel AA release and eicosanoid generation in diverse 
cell types, as implicated by studies in cPLA2 deficient mice (Snyder, 1995).  Stimulation by 
calcium ionophore (A23187) has been shown to cause the production of PAF in peritoneal 
cells (Ninio et al., 1983), and stimulation by A23187 or formyl-methionyl-
leucylphenylalanine has a similar effect on eosinophils.  PAF expression has been reported in 
the estrogen dependent MCF-7 and T47D human breast cell lines, and also in the estrogen 
independent cell line MDA-MB 231.  However, PAF production has not been identified in 
the immortalized nontumor forming breast cell line MCF-10.  In vivo studies have suggested 
that PAF is associated with the stimulation of tumor angiogenesis (Bussolati et al., 2000).   
This has been further supported by a study done by Montrucchio et al. (1998), in which PAF 
was detected in 18 primary breast carcinoma tissues and the amount of PAF correlated with 
tumor vascularization.  
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Lysosomal PLA2’s: 
The lysosomal PLA2’s are a recent addition to the PLA2 superfamily.  They exhibit 
transacylase, Ca
2+ 
-independent PLA2 activity, and 1-O acylceramide synthase (ACS) activity 
(Hiraoka et al., 2002).  They have a size of 45 kDa.  The deficiency of lysosomal PLA2’s has 
been implied to be responsible for the pathologic condition, phospholipidosis (Abe et al., 
2007).  
 
CYTOSOLIC PHOSPHOLIPASE A2 (cPLA2): 
In humans, the cPLA2 family consists of 4 isoforms including cPLA2α, cPLA2β, 
cPLA2γ, and cPLA2δ.  In a different nomenclature system, they are referred to as group IVA, 
IVB, IVC, and IVD respectively (Schaloske and Dennis, 2006).  Each of the 4 isoforms 
contains a divided catalytic region consisting of domains A and B.  These domains include 
conserved amino acids required for enzyme catalysis, and are linked by isoform specific 
amino acid sequences (Murakami and Kudo, 2002).  The lipase consensus sequence 
(GXSGS) is located close to the N-terminal region of the A domain (Fig. 1).  The N-termini 
of both cPLA2α and cPLA2β, have a Ca
2+ 
binding domain (CaLB domain) (Fig. 1), that 
regulates enzyme association to the phospholipid membranes (Murakami and Kudo, 2002; 
Song et al., 1999).   
cPLA2γ shares 29% sequence homology with cPLA2α but lacks the CaLB domain 
that is present in cPLA2α and -β (Fig. 1).  cPLA2γ is constitutively bound to cell membranes, 
and unlike cPLA2α and cPLA2β, membrane attachment in cPLA2γ is dependent on lipid 
modifications of the protein (Song et al., 1999).  cPLA2γ contains putative acylation sites and 
a C-terminal prenylation site that may regulate its membrane association (Pickard et al., 
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1999).  Northern blot analysis indicates that the mRNAs of the cPLA2α, -β, and -γ are widely 
distributed in human tissues, however expression levels do vary between tissues (Pickard et 
al., 1999).  Although there are similarities in the catalytic domains of cPLA2α, -β, and -γ, 
initial biochemical analyses indicate that each of them may have different substrate 
specificity and, probably, activation characteristics (Pickard et al., 1999; Song et al., 1999). 
 
 
 
Fig. 1: Schematic diagram of the homologous protein domains of the cPLA2 isoforms. 
The percentage of identical amino acids to cPLA2α is shown below the homologous domains 
in cPLA2β and cPLA2γ. The conserved serine in the lipase consensus sequence is shown in 
catalytic domain A of each cPLA2 isoform. The positions of the phosphorylated serines in 
cPLA2α is shown.  Adapted from Song et al.,1999.   
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cPLA2α:  
cPLA2α has been mapped onto chromosome 1 and comprises 18 exons that encode 
749 amino acids with a molecular mass of 85 kDa.  cPLA2α is a cytosolic protein that 
preferentially cleaves AA containing phospholipids, and displays Ca
2+
 dependent 
translocation to the perinuclear membranes (Hirabayashi and Shimizu, 2000).  Select 
receptor stimulation elicits a rapid increase in free intracellular Ca
2+
, which triggers the 
translocation of the cPLA2 isozyme (cPLA2α) from the cytosol to the nuclear envelope, 
endoplasmic reticulum, and the golgi apparatus where its substrate is located (Grewal et al., 
2002; Grewal et al., 2003).  MAPK and MAPK-activated kinases are usually responsible for 
activation of cPLA2α via phosphorylation at Ser
505 
and Ser
727
 respectively (Hefner et al., 
2000); it can also be activated by phosphorylation via the calcium/calmodulin kinase II 
pathway at Ser
515
(Muthalif et al., 2001).  Under such stimulated conditions the rate of AA 
release exceeds the rate of its reacylation, allowing free AA to accumulate and thereby 
rendering it available for eicosanoid production.  In the majority of cells and tissues there is a 
constitutive expression of cPLA2α, allowing it to play significant roles in both immediate and 
delayed eicosanoid biosynthesis (Brash, 1999; Fitzpatrick and Soberman, 2001; Fujishima et 
al., 1999; Murakami et al., 1999; Smith et al., 2000).    
The Ca
2+
 dependent translocation of cPLA2α to the intracellular membranes is a 
crucial step in the initiation of stimulus-coupled AA release.  In fact, phosphorylation of 
cPLA2α per se is insufficient to cause AA release without an increase in Ca
2+
, suggesting 
phosphorylation plays an augmentative role in cPLA2α activation.  In addition to 
transcriptional regulation, cPLA2α also undergoes post-transcriptional regulation.  As 
reported by Tay et al. (1994), in rat mesangial cells, phorbol myristate acetate, platelet 
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derived growth factor, serum and epidermal growth factors increase the half-life of cPLA2α 
mRNA (Clark et al., 1995).  Studies on the isolated CaLB domain have indicated a 
preference of binding to phosphatidylcholine vesicles in the presence of µM levels of Ca
2+
 
(Nalefski et al., 1998).  Several proteins have been shown to regulate cPLA2α activation.  
Vimentin (Nakatani et al., 2000), a protein abundant in the perinuclear region, and nuclear 
cPLA2α-interacting protein (PLIP) (Sheridan et al., 2001) positively regulate cPLA2α 
mediated AA release (Six and Dennis, 2000).  Calpactin light chain (Wu et al., 1997) and 
annexin I (Kim et al., 2001) inhibit cPLA2α function.  However the physiological relevance 
of these regulatory proteins requires further clarification (Murakami and Kudo, 2002).  
The cPLA2α gene regulatory region includes potential binding sites for AP-1, AP-2, 
NF-κB, C/EBP, PEA3, OCT, and GRE (Miyashita et al., 1995).  The cPLA2α promoter does 
not include a TATA box or a GC rich region, or SP1 sites, making it distinct from typical 
housekeeping genes.  The 5’-flanking region contains a 27-base pair motif that consists of a 
polypyrimidine sequence which reportedly is responsible for the basal expression of cPLA2α 
(Miyashita et al., 1995).  In cultured endothelial cells, the intracellular distribution of cPLA2α 
depends on cell density.  At high cell density the cPLA2α isozyme is primarily localized in 
the cytosol and cell junctions, whereas in subconfluent cell cultures it appears to reside in the 
nucleus (Hirabayashi and Shimizu, 2000).  
Stimulation by cytokines and mitogens such as IL-1β, TNFα, EGF, colony 
stimulating factor, c-Kit ligand, IFNγ antigens, UV light, and other agonists moderately 
induces the expression of cPLA2α in various cell models (Clark et al., 1995).  Increased 
cPLA2α synthesis upon induction by IL-1β correlates with PGE2 production, while the 
glucocorticoid dexamethasone, suppresses both cPLA2α and PGE2 production without 
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affecting the cyclooxygenases levels (Lin et al., 1992).  In some cell models a coordinated 
upregulation of cPLA2α and COX-2 has been observed (Clark et al., 1995).    
 
Pathogenesis of cPLA2α. The cPLA2α isoform is involved with numerous pathologies 
including inflammatory disorders, intestinal ulceration, and brain injury (Bonventre and 
Sapirstein, 2002; Sapirstein and Bonventre, 2000; Sun et al., 2004).  Several studies have 
found variation in expression levels and activity of cPLA2α in cancers such as 
cholangiocarcinomas (Wu et al., 2002) and non-small cell lung squamous carcinomas 
(NSCLC) (Nakanishi and Rosenberg, 2006).  In NSCLC, cPLA2α expression is associated 
with the presence of oncogenic Ras mutations (Nakanishi and Rosenberg, 2006), and the 
association of Ras with cPLA2α and COX-2 expression has been suggested to be a potential 
mechanism of maintaining a high level of PGE2 production and, thereby, supporting a 
cancerous state.   
cPLA2α pathology and function has been analyzed in cPLA2α deficient mice.  
cPLA2α knockout mice display a compromised generation of eicosanoids and PAFs, and 
exhibit a marked reduction of airway anaphylactic response, adult respiratory distress 
syndrome, and ischemic brain injury when compared to the wild type mice (Bonventre et al., 
1997; Nagase et al., 2000).  However, perhaps the most important phenotypes observed were 
difficulties in embryogenesis and implantation, a characteristic attributed to the suboptimal 
production of the prostaglandins, primarily PGF2α (Bonventre et al., 1997).  Genetic 
evidence of cPLA2α involvement in the expansion of intestinal polyps in familial 
adenomatous polyposis (FAP) came from studies by Takaku et al. (2000), who introduced a 
cPLA2α deletion into Apc
716
 mice, a model for human FAP.  Mice with disrupted genes of 
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the COXs, 5-LOX, or PG receptors had phenotypes not entirely identical to those of the 
cPLA2α knockout mice, suggesting the involvement of additional PLA2 enzymes (Murakami 
and Kudo, 2004).  The cPLA2α paralogs cPLA2β and cPLA2γ may participate along with 
cPLA2α, or independently in situations when cPLA2α is absent, thus providing AA for 
eicosanoid generation.  Moreover, sPLA2 activity is dependent on cPLA2 in several 
circumstances (Balsinde et al., 1998; Murakami et al., 1999). 
cPLA2α has been suggested to be involved in TNFα mediated apoptosis (Obeid and 
Hannun, 1995).  Usage of AACOCF3, a cPLA2α inhibitor, protected colonocytes from TNFα 
induced apoptosis (Dong et al., 2003).  The cPLA2 deficient L929 cell line is resistant to 
TNFα-induced apoptosis (Hayakawa et al., 1993).  The apoptotic response is restored when 
cPLA2α is expressed in the cells by transfecting with cPLA2α cDNA (Hayakawa et al., 
1993).  However, many cells are resistant to TNFα induced apoptosis (Voelkel-Johnson et 
al., 1996), and the role of cPLA2α in TNFα induced apoptosis remains unclear.   
 
cPLA2β:  
cPLA2β was originally cloned from libraries of human brain and pancreas.  It maps to 
chromosome 15, has 6 exons, and encodes a protein of 110-114 kDa (Pickard et al., 1999; 
Song et al., 1999).  cPLA2β mRNA is expressed in different human tissues, with higher 
expression in the pancreas, liver, heart, and brain (Song et al., 1999).  The mRNA of cPLA2β 
is found predominantly in an unspliced form (8.5 kb) rather than its completely spliced form 
(3 kb) (Song et al., 1999).  The cPLA2β protein is expressed at varying levels in different 
human tissues such as the liver, brain, lung, spleen, kidney, pancreas, heart, testis, and ovary 
(Ghosh et al., 2006a).  Comparison of the amino acid sequences of cPLA2α and cPLA2β 
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showed approximately 30% homology (Pickard et al., 1999).  There is a 242 amino acid (aa) 
sequence in the cPLA2β amino (N) terminal domain, that has no homology to cPLA2α or 
cPLA2γ (Song et al., 1999).  Subsequent sequence analysis revealed that this 242 aa sequence 
bears homology to the human JmjC domain (Clissold and Ponting, 2001).  However this 
domain has no effect on cPLA2β’s enzymatic activity as its deletion did not affect the 
enzyme’s specific activity as compared to the full length cPLA2β protein (Song et al., 1999).   
 
cPLA2β  regiospecificity and calcium sensitivity. In vitro studies performed by Song et al. 
(1999) and Pickard et al. (1999), showed that PLA2 activity of cPLA2β was much lower than 
that of cPLA2α.  cPLA2β displayed a similar preference for 1-[
14
C]palmitoyl-2-arachidonyl-
PC (*PAPC) and 1-palmitoyl-2-[
14
C]arachidonyl-PC (P*APC) as it did for1-O-hexadecyl-2-
[
3
H]arachidonyl-PC (O-H*APC).  In the vesicle assays, cPLA2β initially exhibited 
regiospecificity toward sn-1 palmitic acid (PA) from *PAPC, followed by the release of sn-2 
AA from O-H*APC (Song et al., 1999).  cPLA2β enzymatic activity is Ca
2+
 dependent, as 
indicated by experiments in which the phospholipase activity was strictly dependent on the 
presence of Ca
2+
.  Chelating Ca
2+
 with EGTA caused the loss of phospholipase activity (Song 
et al., 1999).  It has been suggested that the membrane association of cPLA2β is dependent on 
the CaLB domain (Channon and Leslie, 1990; Schievella et al., 1995; Song et al., 1999).   
 
Pathogenicity of cPLA2β. A recent study investigated the presence of the PLA2 isoforms in 
immature blasts of patients with acute myeloid and acute lymphoid leukemia (Fiancette et al., 
2009).   qRT-PCR analysis indicated that cPLA2α and cPLA2β had similar mRNA expression 
levels in the leukemic blasts, while the expression of cPLA2γ was the least among the 3 
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isoforms (Fiancette et al., 2009).  No other reports are currently available on the involvement 
of cPLA2β in disease conditions.   
 
cPLA2γ:  
cPLA2γ maps to chromosome 19, and is composed of 17 exons that code a 541 amino 
acid polypeptide with a predicted molecular mass of 61 kDa.  Despite sharing about 29% 
homology with cPLA2α (Hartmann et al., 2002; Pickard et al., 1999), as well as harboring the 
residues utilized in cPLA2α for its catalytic activity, cPLA2γ is structurally and functionally 
different from cPLA2α.  In contrast to cPLA2α, whose activity is regulated by 
phosphorylation at Ser 505 by MAPK, cPLA2γ has protein kinase C phosphorylation sites 
that may regulate its enzymatic activity (Underwood et al., 1998).  Unlike cPLA2α and -β, 
cPLA2γ is constitutively bound to cell membranes.  The membrane association of cPLA2γ 
remains unaltered upon mutation of the C-terminal prenylation site, suggesting that this site 
individually is not responsible for membrane binding.   cPLA2γ contains myristoylation, 
several palmitoylation, and acylation sites (Tucker et al., 2005).  It has been suggested that 
fatty acylation, together with farnesylation, may be responsible for the constitutive 
membrane association of cPLA2γ (Ghosh et al., 2006b).     
Studies with cPLA2γ transfected cells demonstrated that the enzyme may be localized 
to the perinuclear membranes.  When N-terminal GFP-tagged cPLA2γ was overexpressed in 
HEK293 and CHO cells, the enzyme was associated with the endoplasmic reticular and golgi 
membranes (Asai et al., 2003; Murakami et al., 2003).  However, when the untagged cPLA2γ 
was overexpressed in skeletal muscle cells, lung fibroblasts, and COS7 cells, the enzyme was 
associated with the mitochondria (Tucker et al., 2005).     
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cPLA2γ regiospecificity. Initial studies by Song et al. (1999) indicated that cPLA2γ can 
liberate sn-1 PA and sn-2 AA with equal potency using *PAPC and O-H*APC as substrates.  
A follow up study using purified cPLA2γ displayed that it can release sn-2 AA using 1-O-
hexadecyl-2-arachidonyl-phosphatidylcholine as substrate but not sn-1 PA from 1-palmitoyl-
2-O-hexadecyl-phosphatidylcholine (Stewart et al., 2002).  However when 1-palmitoyl-2-
arachidonyl-phosphatidylcholine was the substrate, cPLA2γ first hydrolyzed sn-2 AA and 
then the sn-1 PA (Stewart et al., 2002).  This suggests that cPLA2γ sequentially hydrolyzes 
the sn-2 fatty acids followed by sn-1 hydrolysis (Hirabayashi and Shimizu, 2000; Murakami 
et al., 2003; Stewart et al., 2002; Underwood et al., 1998).  In a separate study done by 
Murakami et al. (2003), the enzymatic efficiency of cPLA2γ for sn-2 AA was 2-fold greater 
when compared to sn-2 oleic acid (OA).  In HEK293 cells, cPLA2γ released AA, OA, PA, 
and stearic acid in a serum dependent manner, suggesting cPLA2γ may have a role in 
phospholipid remodeling (Asai et al., 2003; Murakami et al., 2003; Stewart et al., 2002).   
cPLA2γ is involved in H2O2-induced AA release in cPLA2γ-overexpressing HEK293 
cells, although the exact mechanism of this activation has not been determined (Asai et al., 
2003).  In the same study, the use of a PKC inhibitor, calphostin C, did not affect the release 
of AA.  However a protein tyrosine kinase inhibitor, herbimycin A, inhibited release (Asai et 
al., 2003).  Orthovanadate (Na3VO4), a protein tyrosine phosphatase inhibitor, surprisingly 
enhanced the AA release by cPLA2γ.  The induction of cPLA2γ by H2O2, leading to AA 
release, indicates that cPLA2γ may release AA in response to oxidative stress (Asai et al., 
2003).                    
Although cPLA2γ lacks the CaLB domain present in cPLA2α and -β, stimulating cells 
that overexpress cPLA2γ by Ca
2+
 ionophore A23187 increases free AA levels and COX-1 
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mediated PGE2 production compared to control specimens (Murakami et al., 2003).  It has 
been suggested that although cPLA2γ is Ca
2+
 independent, increases in Ca
2+
 levels stimulates 
mitochondrial production of ROS, which may be responsible for the regulation of 
mitochondrial associated cPLA2γ activity (Ghosh et al., 2006b).  Most of the findings on 
cPLA2γ discussed here have been obtained from studies on cells overexpressing the isozyme, 
thus the regulation and activity of endogenous cPLA2γ is uncertain.  In one study by Duan et 
al. (2001), the mRNA and protein of cPLA2γ was elevated in human macrophages infected 
by Mycobacterium tuberculosis.  cPLA2γ may have varied physiological roles due to its 
ability to act as a PLA2, transacylase, or lysophospholipase.   
Among all of the PLA2 categories, cPLA2 appears to be the principal activator for the 
release of AA used in eicosanoid production, at least during the early stage of eicosanoid 
synthesis (reviewed in Balsinde et al., 1999).  In some instances eicosanoid production 
persists over several hours and during these situations, sPLA2, along with cPLA2, may 
contribute substrate for the delayed production of eicosanoids (Balsinde et al., 1999).  
Interestingly, blockage of cPLA2 has been shown to eventually shut off sPLA2 production 
and therefore, sPLA2-dependent biological responses (Balsinde et al., 1998).  In mammalian 
cells, regulation of AA production takes place by the interplay of an array of PLA2 enzymes 
in different tissues; therefore understanding the regulation, function and expression of each 
PLA2 is important in order to decipher its role in any disease.  
 
cPLA2 and Breast Cancer: 
          Extensive evidence is available on the physiological and pathological implications of 
cPLA2α.  Differential expression of the cPLA2 isoforms in various tissues, suggests the need 
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to investigate the roles played by the other members of the cPLA2 family.  cPLA2α 
expression is elevated in several human tumors, such as colorectal (Wendum et al., 2005), 
small bowel (Wendum et al., 2003), lung (Heasley et al., 1997), and prostate cancer (Patel et 
al., 2008).   Estrogen activates the prostanoid signaling pathway through the activation of 
cPLA2α in the MCF-7 breast cancer cell line (Thomas W, 2006).  In murine models, cPLA2α 
expression is considered to be pro-tumorigenic (Hong et al., 2001).  Although numerous 
studies have implicated the eicosanoids in cancer onset and progression (Markaverich et al., 
2007; Nie et al., 2001; Pan et al., 2008; Sveinbjornsson et al., 2008), limited work has been 
conducted on the cytosolic phospholipase A2 (cPLA2) isozymes that are believed to provide 
the AA utilized for eicosanoid synthesis (Adler et al., 2008).  Little is known about cPLA2β 
and cPLA2γ, and any roles played by these isozymes in breast cancer are yet to be 
determined. 
 
RESEARCH PROJECT OBJECTIVES: 
Dysregulated lipid metabolism appears to be important in breast cancer biology.  
Despite an acknowledged fundamental role of cPLA2 in eicosanoid biosynthesis, limited 
cancer related studies have been directed towards this phospholipase.  cPLA2α is elevated in 
several human tumors (Heasley et al., 1997; Wendum et al., 2005).  Whether cPLA2β or 
cPLA2γ can contribute to AA release as a substrate for the eicosanoid producing enzymes is 
yet to be demonstrated, and they have not been investigated in connection with breast cancer.  
There is abundant evidence that the AA metabolites, including prostaglandin E2 and HETEs, 
play significant roles in the onset and progression of several cancers, including breast cancer 
(reviewed in Nie et al., 2001; Winer et al., 2002).  Therefore, defining and characterizing the 
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enzymatic pathways responsible for AA release may be critical to the understanding of breast 
cancer biology, and may contribute to effectively treating the disease.  The studies reported 
herein were undertaken to investigate the expression of the cPLA2 isozymes -α, -β, and -γ in 
the breast cancer cell line models MDA-MB231 and MCF-7, and in the immortalized non-
tumorigenic breast cell line MCF-10A.  Additionally, surgically removed cancerous human 
breast tissue was also screened for the cPLA2 isozyme protein expression, and is compared 
with the results from the cell lines.  
The MCF-7 cell line is characterized by the presence of the estrogen receptors ERα 
and ERβ (Fabbro et al., 1986; Hall et al., 1990) and is the best characterized, and most widely 
utilized, model of an estrogen-responsive breast cancer cell line.  In vivo studies have 
demonstrated a low invasive capability of these cells (Thompson et al., 1992).  The basic 
EGF receptor and several MMPs are absent in these cells.  The MDA-MB-231 cell line is a 
highly invasive cell line and displays the loss of E-cadherin (Pierceall et al., 1995), and 
estrogen and progesterone receptors (Cailleau et al., 1978).  The MCF-10A cells display the 
absence of a tumor-inducing capability in mice, show anchorage-dependent growth, and 
grow in culture only in the presence of hormones and growth factors (Soule et al., 1990).  
These characteristics appear to make MCF-10A useful as a control cell line model of human 
breast tissue.    
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MATERIALS AND METHODS  
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Reagents:  Recombinant tumor necrosis factor (TNFα) and recombinant interleukin-1β (IL-
1β) were purchased from R&D Systems (Minneapolis, MN).  A23187, epidermal growth 
factor (EGF), hydrocortisone, and insulin were purchased from Sigma Aldrich (St Louis, 
MO) and arachidonyl trifluoromethyl ketone (AACOCF3) from Calbiochem (EMD 
Chemicals Inc., New Jersey).  Stock solutions were prepared according to supplier’s 
instructions and stored at -20
o
C.   
Cell Culture Conditions:  Human mammary tumor cell lines MDA-MB 231 and MCF-7, 
and the normal human mammary cell line MCF-10A were purchased from ATCC (Manassas, 
VA).  Cells were maintained in a 1:1 ratio of Dulbecco’s Modified Eagle Medium (DMEM) 
and Ham’s F-12 medium.  The growth medium of both the MDA-MB 231 and MCF-7 cell 
lines was supplemented with 10% heat-inactivated fetal bovine serum (FBS), Penicillin: 
Streptomycin: Neomycin (PSN; 1%), and glutamine (2 mM; Biofluids, Rockville, MD).  The 
MCF-10A growth medium was supplemented with 5% heat-inactivated FBS, PSN (1%), 
glutamine (2 mM), EGF (20 ng/ml), hydrocortisone (0.5 µg/ml), and insulin (10 µg/ml).  Cell 
cultures were maintained in a 5% CO2, 37
o
C humidified incubator.  All experiments were 
performed with cells in passages 5-30.  
Tissue:  Breast cancer tumor specimens were obtained from the Tissue Bank of the West 
Virginia University Health Science Center.  Samples were obtained in microfuge tubes 
containing 200 µl lysis buffer (composition described later).  The tubes were snap frozen and 
stored in -80
o
C until used.  Five tumor samples were assessed in these studies.   The 
pathologic (p) staging of tumors includes the letters T, N and M, where T stands for tumor, N 
for lymph nodes and M for metastasis.  T is followed by a number between 0 and 4 and the 
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number assigned depends on the tumor size and spread to the skin or the chest wall under the 
breast.  A higher T indicates a larger tumor and/or wider spread to the tissues near the breast.  
The letter N is followed by a number between 0 and 3 implying the spread of the cancer to 
the lymph nodes near the breast and the number of lymph nodes affected.  The letter M is 
followed by 0 or 1, respectively, indicating the absence or presence of spread to distant 
organs.  X indicates no assessment of any given criteria (American Cancer Society, 2009).  
Tumor sample I was from a 43 year old female diagnosed with invasive ductal carcinoma 
staged at pT2N1aMX.  Tumor sample II was from a 42 year old female diagnosed with 
infiltrating ductal carcinoma staged at pT2N1aMX.  Tumor sample III was from a 48 year 
old female diagnosed with infiltrating ductal adenocarcinoma staged at pT1b,pN0(i-).  Tumor 
sample IV was from a 64 year old woman, diagnosed with invasive ductal carcinoma and 
staged at pT1aN0MX and Tumor sample V was from a 54 year old woman, diagnosed with 
invasive ductal carcinoma and staged at pT1c (sn)N0(i-)MX. 
Construction of expression vectors for molecular cloning of cPLA2α fragments for the 
generation of the cPLA2α antibody:  Amino acid sequences corresponding to cPLA2α 
(411-442) are gene specific (GenBank
TM
 accession number CAB42689) and comprise an 
antigenic segment considered appropriate for antibody generation (Princeton Biomolecules, 
PA (Welling et al., 1985)).  Gene specific primer sets containing BamHI and XhoI restriction 
enzyme sites (lower cases) were synthesized to amplify the above mentioned fragment of 
cPLA2α as follows: forward primer 5’-ggatccaaCAAAGCAGAGGCTCCACAATG-3’ and 
the reverse primer  5’-ctcgagGGAGACAGTGGATAAGATGTA-3’.  Reverse-transcription 
polymerase chain reaction (RT-PCR) was used to amplify the cPLA2α gene specific fragment 
using MCF-7 cell RNA.  To overcome the difficulty of cloning for gene sequence specificity 
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conformation, larger fragments than those necessary were amplified for antibody generation.  
For gene fragment specificity determination, the RT-PCR amplified fragments were purified 
(Qiagen), followed by ligation into pBSIISK
+
 vector, and cloned in DH-5α cells (the 
generous gift of Dr. Bidwai, West Virginia University, Morgantown, WV).  The transformed 
cells were grown and the plasmids of two representative clones were isolated, sequenced 
(Retrogen Sequencing, CA), and gene fragment specificity confirmed (Blast, GenBank, 
NCBI).  
Site Directed Mutagenesis: To ensure the expression of only the specific antibody 
fragments as GST-fusion fragments, a stop codon was introduced in the cPLA2α plasmid 
using the Quick-Change site directed mutagenesis kit (Stratagene).  Both the forward and 
reverse primer sets contained the stop codon (underlined sequence).  Only the forward primer 
sequence is shown:  the Glu
443
 (GAA) was substituted with stop codon, 5’-
GGACAGTGATGATGAATCACACTAACCCAAAGGCACTGAAAATGAAGAT--- 
GCTGG-3’.  The plasmid containing the cPLA2α antibody fragment was subjected to 20 
cycles of polymerase chain reaction (PCR) using the primer sets described above.  The PCR 
products were digested with the DpnI enzyme to eliminate the non-mutant plasmids that were 
used as templates.  The reaction mixture was used to transform E. coli DH5α cells.  
The above described section on the generation of the cPLA2α construct for antibody 
generation was conducted previously in the lab (Maricica Pacurari, 2006).  The PBSIISK
+
 
plasmids of cPLA2α from two representative clones were sequenced using T7 primers to 
confirm the specificity of the gene fragment and also to confirm the presence of the stop 
codon (Blast, GenBank, NCBI).  The cDNA fragments encoding the specific antibody 
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fragments were subcloned into BamHI-XhoI sites of pZEX vectors, cloned in E. coli (BL21-
DE3) cells that possess the plasmid pT-TRX for expression and purification of GST-fusion 
proteins (gifts of Dr. Bidwai).  
Purification of Glutathione S-Transferase (GST) fusion peptides:  Cultures were grown 
in 2xYTA containing 150 µg/ml ampicillin and 10 µg/ml chloramphenicol to an OD600 
between 0.5 to 0.7.  The culture was then induced with 1 mM isopropyl-β-D-thiogalactoside 
(IPTG) for 3 hours at 30
o
C with vigorous shaking (225 rpm).  The cells were harvested and 
resuspended in phosphate buffered saline (PBS) containing 100 mM phenylmethylsulfonyl 
fluoride (PMSF), 0.8% 2-mercaptoethanol and mixed overnight at 4
o
C.  The next day the 
cells were lysed by sonication until 95% of cells were lysed as indicated by phase contrast 
microscopy (Nikon).  Triton X-100 was added to a final concentration of 1% and the cell 
homogenate was mixed for 3 hours at 4
o
C.  Following centrifugation, the cell homogenate 
was mixed with 1 ml of glutathione-Sepharose beads (GE Heathcare) overnight at 4
o
C.  The 
column was washed thrice with 10 bed volumes of PBS with 100 mM PMSF.  The bound 
proteins were eluted with 2 ml of 10 mM reduced glutathione in 50 mM Tris-Cl, pH 8.0.  The 
purity and relative concentrations of the eluted proteins was determined by SDS-
polyacrylamide gel electrophoresis (PAGE) relative to standard bovine serum albumin (BSA) 
detected by Commassie Blue staining.  
Production of polyclonal antibodies to cPLA2α: Approximately 5mg of the purified GST-
fusion peptide of cPLA2α was sent to a commercial facility (Cocalico Biologicals Inc, PA) 
for antibody generation.  
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Maltose-binding protein fusion peptides expression: cPLA2α peptide was excised from the 
pZEX plasmid following ligation into PQE-82L plasmid, excised and ligated into pMAL-c2x 
plasmids (New England Biolabs Inc) for in vitro expression as maltose-binding protein 
(MBP) fusion peptides.  The eluted fusion peptides were quantified by the Bradford Assay 
(BioRad) and their purity was determined by SDS-PAGE.   
Dot blot analysis for crossreactivity/specificity analysis of cPLA2α polyclonal antibody:  
Different amounts of MBP-fusion peptides ranging from 0.001 to 3 µg along with MBP and 
GST alone were dot blotted onto nitrocellulose membranes.  The nitrocellulose membranes 
were air dried at room temperature and subjected to standard Western blot analysis as 
described later.  The molecular weight (MW) of MBP expressed from a derivative of pMAL-
c2x, including the amino acid residues coded for by the polylinker up to the Xmn I site is 
42.482 kDa (New England Biolabs Inc).  The molecular weight of the cPLA2 peptide was 
calculated from the peptide sequence using ExPASy (http://www.expasy.ch/tools/pi_tool.html).  
The calculated molecular weight (kDa) of the cPLA2 α peptide (32 aa) was 3.56 and that of 
the MBP- cPLA2α peptide was 46.046.  
Western Blot:  The cell lines (MDA-MB 231, MCF-7 and MCF-10A) were trypsinized and 
subcultured into 6 well plates at 200,000 cells/well and allowed to attach and recover for 24 
hours in 10% FBS supplemented media.  Media were replaced with 2% FBS containing 
media for 96 hours with a refeeding at 48 hours.  Following this preincubation period, TNF-α 
and/or IL-1β were added to fresh 2% FBS media.  Cells were washed once with 1x PBS, 
incubated for 10 mins in 1x PBS with 1 M EDTA at 37
o
C, scrapped, pelleted, and 
resuspended in lysis or homogenization buffer.  For whole cell lysates, the cell pellet was 
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resuspended in 200 µl lysis buffer (20 mM Tris-Cl, pH 7.4, 2 mM Na3VO4, 1 mM NaF, 100 
mM NaCl, 2 mM EDTA, 0.1% SDS, 1% NP-40, 1 µl/ml Sigma’s Protease Inhibitor 
cocktail
TM
, 1 mM PMSF), and for microsomal preparations, the cell pellets were resuspended 
in 200 µl of homogenization buffer (10 mM HEPES, 8% sucrose, 1 µl/ml Sigma’s Protease 
Inhibitor cocktail
TM
, 1 mM PMSF).  Cell debris was removed by microcentrifugation for 15 
minutes at 13,500 rpm at 4
o
C.  For microsomal preparations, cell supernatants were subjected 
to ultracentrifugation at 100,000 x G for 1 hour at 4
o
C (Sorvall).  Cytosolic fractions were 
collected and the pellets were resuspended in homogenization buffer and recovered by 
tituration.  Protein content of the whole cell lysates and microsomal preparations were 
quantified using the Bradford Assay (BioRad).  50 µg of protein per sample was separated on 
10% SDS-PAGE gels and transferred to nitrocellulose membranes.  Protein transfer was 
visualized by Ponceau-S staining.  The membranes were washed 3X with TBST (Tris-
Buffered Saline, 0.1% Tween-20) and were blocked for 2 hours in 2.5 % non-fat dry milk 
TBST blocking buffer and were incubated overnight at 4
o
C with specific primary antibody.  
The primary antibody was removed and the membranes were washed 3X with TBST, 
following which they were incubated with an alkaline phosphatase conjugated secondary 
antibody and developed with Nitro-Blue-Tetrazolium (NBT): Bromo-Chloro-Indolyl- 
Phosphate (BCIP) solution.  The reaction was stopped with 0.5 M EDTA and bands were 
analyzed using the ImageJ software (NIH).  Positive and negative control experiments were 
performed using the MBP-cPLA2 isoform antigenic peptide.  
Western Competition Assays: To confirm antibody specificity for each of the cPLA2 
isoforms, in vitro expressed MBP-fusion peptides (30 µg peptide/ml of antisera) were 
preincubated with isoform specific polyclonal serum for 24 hours at 4
o
C.  
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Immunohistochemistry:  MDA-MB 231, MCF-7 and MCF-10A cells were subcultured 
onto gelatin coated coverslips in 6 well plates at 100,000 cells per well and allowed 24 hours 
in 10% FBS supplemented media to recover from trypsinization and attach.  Media were 
replaced with 2% FBS containing media for 48 hours with a refeeding at 24 hours.  
Following this preincubation period, the cells were washed twice in warm 1x PBS and 
A23187 (5 µM) and AACOCF3 (10 µM) treatments were applied to select specimens.  
Following treatment, the cells were fixed in 4% paraformaldehyde at 4
o
C.  After fixation, 
cells were washed 4X in PBS buffer (1x PBS, 0.1X Triton-X and 1% BSA), and incubated 
overnight at 4
o
C with primary antibody.  The cells were washed 4X with PBS buffer and 
Alexafluor conjugated secondary antibody was applied.  Coverslips were mounted on slides 
with Vectashield mouting media (Vector Labs, CA) and visualized with the Olympus 
FluoView (FV1000) confocal microscope.  
Tissue: Tumor tissue samples immersed in lysis buffer (composition described earlier) were 
sonicated on ice at low power (7) for three 10 second bursts with 30 second intervals between 
each burst.  Cell debris was removed by microcentrifugation for 15 minutes at 13,500 rpm at 
4
o
C.  Protein from the tissue lysates was quantified using the Bradford Assay (BioRad) and 
separated on 10% SDS-PAGE gels.  For tumor samples I, II, III, IV and V; 20 µg, 30 µg, 4.8 
µg, 4 µg, and 8 µg protein, respectively, was run in each lane.  Western blotting was 
conducted for cPLA2 isozyme expression.  The amount of protein used in Western blots for 
each tumor varied and it depended on the total protein extracted from each tumor sample 
(Tumor I: 196 µg, Tumor II: 55.6 µg, Tumor III: 33 µg, Tumor IV: 28 µg, Tumor V: 61 µg). 
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Determination of cPLA2antibody titer:  Western blot analysis was performed to 
determine the useful antibody titer for cPLA2detection.  For this analysis, different 
dilutions of the cPLA2 antisera were used against the MBP-cPLA2 (411-442) peptide (Fig 
2B).  An antibody titer that produced good immunodetection against the peptide was selected 
for further protein analysis.  The specificity of the immunodetection was confirmed by 
Western competition analysis, in which the antiserum was preincubated with the specific 
competing peptide.  For the specificity and crossreactivity analysis of the cPLA2 antisera, a 
1:500 antisera dilution was selected.  Although Western blots were conducted on MDA-MB 
231, MCF-7 and MCF-10A cell protein, no cPLA2 (85 kDa) specific band was detected 
(Fig. 3A,B). Initial studies on the cell protein were conducted using a 1:500 dilution of 
antisera; however, in later studies a 1:50 antibody dilution was used.  
 
Analysis of specificity and crossreactivity of cPLA2 antisera:  The cPLA2antisera was 
specific as indicated by dot-blot analysis shown in Fig. 2C.  It did not crossreact with affinity 
purified MBP-cPLA2 (1 - 57) designated as cPLA2, MBP-cPLA2 (808 - 829) designated 
as cPLA2MBP-cPLA2 (307 - 327), or with MBP alone as indicated by Western blot 
analysis as shown in Fig. 2D.   
 
Expression of cPLA2 isoforms in the MDA-MB 231, MCF-7 and MCF-10A cell lines by 
Western blot analyses:  To examine the expression of the cPLA2 isoforms in the human 
breast cancer cell lines MDA-MB 231 and MCF-7 as well as in the non-tumorigenic human 
breast cell line MCF-10A growing in normal growth medium, Western blots were conducted 
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using the cPLA2 isoform specific antisera and the preincubated antisera.  Antibody titers for 
cPLA2, cPLA2and cPLA2 were made as recommended (Maricica Pacurari, 2006).  No 
bands showing the predicted mass of cPLA285 kDa), cPLA2 (110 kDa), cPLA2 (110 
kDa),or cPLA2 (61 kDa) were detected in any of the 3 cell lines tested in three independent 
trials (Fig. 3A-H).  
 
Effect of cytokine treatment on cPLA2 isoform levels in MDA-MB 231 and MCF-10A 
cell lines:  Analyses of the effect of TNF and/or IL-1 on the cPLA2 isoform levels were 
guided by earlier studies in the laboratory conducted on MCF-7 cells.  It was reported that 
TNF increased the expression of the cPLA2 protein and IL-1 elicited an increase in 
cPLA2 mRNA in those cells.  Both TNF and IL-1 have been reported by others to induce 
the expression of cPLA2 in diverse cell models (Clark et al., 1995; Grewal et al., 2003).  No 
bands of the predicted mass of the cPLA2 isoforms were detected from either the MDA-MB 
231 or MCF-10A cell lines upon stimulation with TNF and IL-1 (Fig. 4A-F, Fig. 5A-F).    
 
Distribution of cPLA2 isoforms in the MDA-MB 231, MCF-7 and MCF-10A cell lines:  
To further explore the possible expression of, and the distribution of the cPLA2 isoforms in 
the above mentioned cell lines, immunohistochemistry techniques were employed using 
cPLA2 isoform specific antisera and fluorescent secondary antibodies.  Negative control 
experiments were conducted using antisera preincubated with the corresponding blocking 
peptide and the secondary antibody.  In both MDA-MB 231 (Fig. 6A-E, Fig. 7A-E) and the 
MCF-7 (Fig. 8A-G) cells, fluorescence output was significantly attenuated in cells evaluated 
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with the preincubated antisera suggesting the presence of the cPLA2 isoforms.  These 
observations indicate a cytosolic localization of the cPLA2 isoforms, although further 
investigations are necessary to identify their precise location within each of the cell lines.  No 
detection of cPLA2 isozymes was observed in the MCF-10A cells, and a representative figure 
of the cPLA2 isozymes in the MCF-10A cells done in two independent trials is shown in 
Fig.9A-C.  These results were independent of antiserum preincubation with the blocking 
peptides.  
 
Effects of AACOCF3 on cPLA2 isoforms -α, -β and -γ detection in MDA-MB231 and 
MCF-7 cell lines:   AACOCF3 is an arachidonic acid analogue and an inhibitor of cPLA2, 
cPLA2and cPLA2(Meyer et al., 2005; Riendeau et al., 1994)he effect of AACOCF3 
on the cPLA2 isoforms was assessed in both the MDA-MB 231 and MCF-7 cell lines.  The 
concentration and the time of treatment by AACOCF3 were determined as described in the 
literature (Fatima, 2002; Riendeau et al., 1994; Woo et al., 2000).  As shown in Fig. 10A-F, 
the MDA-MB 231 cells, upon treatment with AACOCF3, demonstrated significantly 
mitigated fluorescence output when assessed for cPLA2cPLA2and cPLA2.  Similar 
results were observed in the MCF-7 cells (Fig. 11A-F).   
 
Relocalization of cPLA2 and cPLA2 in response to Ca
2+ 
ionophore A23187 in MDA-
MB 231 and MCF-7 cell lines:  cPLA2and cPLA2 include a Ca
2+ 
binding domain and 
require Ca
2+
 for functioning.  In unstimulated cells, cPLA2 is reportedly localized in the 
cytosol and after Ca
2+
 stimulation translocates to the perinuclear membranes (Grewal et al., 
2002; Grewal et al., 2003; Schievella et al., 1995).  In the present studies, following the 
49 
 
elevation of cytosolic Ca
2+
 levels by the Ca
2+
 ionophore A23187, a relocation of cPLA2 was 
observed in both the MDA-MB 231 (Fig. 12B, 12C) and the MCF-7 cells (Fig. 13B).  In 
contrast to the unstimulated cells where the cPLA2α signal was diffused in the cytoplasm, in 
the A23187 stimulated cells the signal was concentrated around the nucleus.  
Similar redistribution of the cPLA2 signal was also observed in both the cell lines upon 
treatment with A23187 (Figs. 12E, 12F, and 13D).   
 
Expression of cPLA2 isoforms in cancerous human breast tissue samples:  To assess the 
expression of the cPLA2 isozymes --and -in cancerous human breast tissues, Western 
blot analyses were performed on human breast cancer tissue samples using antisera generated 
against the respective cPLA2 isozymes.  Due to the differential amount of tissue obtained for 
each of the five samples, quantitative analyses could not be performed.  No bands of the 
predicted mass of the cPLA2 isozymes were obtained from any of the five tumor samples 
tested (Fig. 14-18).  Preincubation with the respective blocking peptides did not provide 
evidence of the presence of any of the cPLA2 isoforms (Fig. 14-18).  
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DISCUSSION  
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Arachidonic acid and its bioactive metabolites play significant roles in normal tissue 
homeostasis, inflammation and in several pathophysiological conditions, including cancer.  
The eicosanoids, primarily PGE2, play fundamental roles in tumor development and 
progression and are abundantly expressed in several human cancers including colon, lung, 
and breast (Dohadwala et al., 2002; Schrey and Patel, 1995; Shao et al., 2003).  A significant 
reduction in breast cancer development in mice follows the administration of a PGE2 receptor 
(EP1) antagonist (Kawamori et al., 2001).  PG production from free AA is a multistep 
process catalyzed by the COX-1 and COX-2 enzymes.  COX-2 selective inhibitors limit 
tumor growth in the breast, colon, gall bladder, esophageal, and pancreatic cancers 
(Grossman et al., 2000; Higashi et al., 2000; Ristimaki et al., 2002).   
Typically, free AA is the substrate used for prostaglandin biosynthesis.   In 
unstimulated cells, AA is esterified at the sn-2 position of the cellular glycerophospholipids.  
The release of AA from the cellular glycerophospholipids by the phospholipase A2 (PLA2) 
enzymes rate limits PG biosynthesis (Capper and Marshall, 2001).   The free AA is then 
acted upon by the COX enzymes in a two step conversion into PGH2.  PGH2 can then be 
acted upon by various enzymes to produce the various PGs, often in a tissue specific manner 
(Smith, 1992).  The PLA2 enzymes comprise a family that has been classified into 19 forms, 
and these divided into four groups in humans.  The groups IV PLA2s, also known as 
cytosolic (c) PLA2, appear to be the principal enzyme(s) producing the initial release of AA 
used for prostanoid biosynthesis (reviewed in Balsinde et al., 1999).  The cPLA2 group itself 
is comprised of four isoforms, of which cPLA2cPLA2and cPLA2 (also referred to 
group IVA, IVB, and IVC) were the focus of this study.  Although the cPLA2 isoform has 
long been considered the principal enzyme involved, the participation of the other 
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cPLA2paralogues, cPLA2andcPLA2 must also be considered as potential contributors.  
Our studies show that both the MDA-MB 231 and MCF-7 breast cancer cell lines express the 
cPLA2cPLA2andcPLA2proteins.  However, this was not the case in the non-
tumorigenic human breast cell line, MCF-10A, where the cPLA2 isozymes could not be 
detected.  It will be of interest to determine if tumorigenic potential correlates with cPLA2 
expression in additional model systems. 
cPLA2 is expressed in a wide variety of cell types including platelets, macrophages, 
neutrophils, endothelial cells, vascular smooth muscle cells, alveolar epithelial cells, renal 
mesanglial cells, keratinocytes, and others (Sharp et al., 1991).  Several human tumors, 
including colorectal, small bowel, and lung exhibit elevated expression of cPLA2(Heasley 
et al., 1997; Wendum et al., 2003).  The overexpression of cPLA2has also been reported in 
NSCLC and cholangiocarcinomas (Nakanishi and Rosenberg, 2006).  RT-PCR and Western 
blot analyses revealed varying levels of cPLA2 in several human breast cancer cell lines 
such as SKBR33, UACC893, HCC38, MDA-MB 231, BT474 and MCF-7.  The BT474 and 
MCF-7 cells exhibited significantly lower expression of cPLA2mRNA and protein than the 
other cell lines tested (Caiazza et al., 2010).  Clinical evidence of cPLA2 expression in 
human breast tumors has not yet been reported.    
As was previously reported (Caiazza et al., 2010), we also found that both the MDA-
MB 231 and the MCF-7 cell lines express cPLA2However, to our knowledge this is the 
first immunohistochemical analysis demonstrating the presence of cPLA2α protein in these 
cells.  The present studies also revealed that cPLA2α was predominantly localized in the 
cytoplasm of both the cancer cell lines.  In contrast, the cPLA2α protein was not detected in 
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the MCF-10A cells, an observation not previously reported.  AACOCF3 is an arachidonic 
acid analogue and a potent inhibitor of cPLA2α (Riendeau et al., 1994).  Pretreatment with 
AACOCF3, caused a decrease of cPLA2 signal in the MDA-MB 231 and MCF-7 cells, and 
antigenic adsorption of the cPLA2α antibody with its corresponding blocking peptide (also 
referred to as the pre-incubated cPLA2α antibody) prevented detection of the cPLA2α protein 
in either of the cell lines, providing evidence in support of antiserum specificity.  
cPLA2 remains the most widely studied member of the cPLA2 family, primarily due 
to its selectivity for sn-2 AA.  An approximately 20-fold preference for AA hydrolysis as 
compared to sn-2 PA, has been reported (Clark et al., 1991; Leslie, 2004; Leslie et al., 1988).  
During basal conditions, cPLA2 is primarily located in the cytosol (Grewal et al., 2003; 
Schievella et al., 1995).  Stimulation by a variety of agonists causes relocation of cPLA2 to 
the intracellular membranes.  It has been suggested that the translocation is mediated through 
the CaLB domain, which upon an elevation in intracellular free Ca
2+
, promotes the binding of 
cPLA2to the phospholipids (Gijon et al., 1999; Song et al., 1999).  In the present study, 
stimulation by the Ca
2+
 ionophore A23187 caused a relocation of the immunohistochemically 
detected cPLA2 to the nuclear membranes in both the MDA-MB 231 and MCF-7 cells.  On 
the other hand, in A23187 negative conditions, cPLA2α was predominantly evident in the 
cytoplasm.  Given the observations that the pre-incubated cPLA2α antibody and AACOCF3 
treatment caused a loss or decrease, of cPLA2α signal, implies that the detected signal is 
specific to cPLA2α.  Additionally, A23187 mediated relocation of cPLA2α to the nuclear 
membranes, further suggests that the cPLA2α is expressed in the breast cancer cell lines, 
MDA-MB 231 and MCF-7. 
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Corresponding studies with whole cell lysates of MDA-MB 231, MCF-7 and MCF-
10A cells, were unable to detect cPLA2α by Western blot analyses.  These results seem to 
present a paradox.  Although the actual reason is unknown at this moment, it may be that the 
cPLA2 protein is unstable and is degraded during the disruption of the cells, even with the 
use of protease inhibitors.  Alternatively, the enzymes maybe present at levels below the 
threshold requirement for detection by Western blotting.   Several cytokines, such as IL- or 
TNF and growth factors such as EGF, cause elevated cPLA2 expression in several cell 
types (Hoeck et al., 1993; Hulkower et al., 1992; Maxwell et al., 1993).  However, we found 
by Western blot assays that neither TNFor IL- had any apparent effect on the cPLA2 
protein in either of the cancer cell lines, or in the normal breast cell line model MCF-10A.  
 cPLA2 mRNA and protein is expressed in various human tissues such as the 
pancreas, liver, heart, brain (Ghosh et al., 2006a; Song et al., 1999).  The cPLA2 mRNA is 
predominantly present in an unspliced form, which, after final processing, encodes a protein 
of 110-114 kDa (Pickard et al., 1999).  There is also evidence of a 100kDa cPLA2β splice 
variant in the lung, spleen and ovary (Ghosh et al., 2006a).  Previous RT-PCR studies done in 
this laboratory (Maricica Pacurari, 2006) using MCF-7 cell RNA indicated the presence of 
both the processed cPLA2β and a pre-processed variant (containing intron I).  This was not 
tested on the MDA-MB 231 and MCF-10A cells.   
Due to the presence of cPLA2 mRNA in the spliced and unspliced forms and 
because of the possibility of multiple splice variants, antibodies against cPLA2 were 
generated against two selected regions.  The first antiserum, referred as cPLA2was against 
amino acids (aa) 1-57 corresponding to exon I, and the second, cPLA2 was against region 
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808-829 aa corresponding to exon 6, that is in between catalytic domain A and B (Maricica 
Pacurari, 2006).  In the present study the cPLA2β protein was detected in both the MDA-MB 
231 and MCF-7 cells.  In the MDA-MB 231 cells, the cPLA2β signal was more intense using 
the cPLA2 antibody than the cPLA2antibodyWhether this reflects actual distinctions 
in the amounts of the cPLA2 protein cannot be determined based on these results.  Antisera 
characteristics might independently yield unique results.  In the MCF-7 cells; cPLA2β was 
detected only with the cPLA2antibody.  Subsequent studies were conducted using the 
cPLA2 antibody.  The cPLA2 signal could not be detected in the MCF-10A cells assayed 
with either of the cPLA2β antibodies.  The cPLA2β antibody blocked with the corresponding 
blocking peptide did not detect cPLA2β in either the MDA-MB 231 or MCF-7 cells, 
suggesting that the signal is specific to cPLA2β. 
It has been proposed that AACOCF3 can also serve as an inhibitor of cPLA2β and 
cPLA2(Meyer et al., 2005), as well as inhibiting cPLA2.  In the present study AACOCF3 
treatment caused a decrease in the cPLA2 signal in the MDA-MB 231 and MCF-7 cells in 
the immunohistochemistry assays.  Based on the apparent physical change elicited, these 
results support Meyer’s (2005) proposition that AACOCF3 may be a cPLA2β inhibitor.  
Similar to cPLA2α, cPLA2β also harbors a CaLB domain and exhibits calcium dependent 
phospholipase activity (Song et al., 1999).  Therefore, it was speculated that cPLA2β protein 
may also be sensitive to A23187 treatment.  In the studies described here, we did observe 
A23187 dependent redistribution of cPLA2β to the perinuclear region in both the MDA-MB 
231 and the MCF-7 cells.  In the absence of A23187, cPLA2β was predominantly located in 
the cytoplasm.   
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In parallel studies, the cPLA2 protein was not immunodetected by Western blotting 
in total cell protein preparations from any of the cell lines tested.  There are no reports from 
other laboratories on the regulation of cPLA2 and whether or not its expression can be 
upregulated, or by what stimuli.  In the present study there was no effect of either TNF- or 
IL-1 on the cPLA2 protein in any of the 3 cell lines when tested by Western blotting.  
However there are possibilities that the cPLA2 protein is unstable and was degraded during 
cell disruption, despite the use of protease inhibitors, or it may present at a level below the 
sensitivity of Western blotting.   
The cPLA2 isoform shares 29% homology with cPLA2, however, unlike 
cPLA2it is Ca
2+
 independent.  In contrast to the widely expressed cPLA2α and cPLA2β, 
cPLA2γ is predominantly found in the skeletal and cardiac muscle, and to a lesser extent in 
the brain (Pickard et al., 1999; Underwood et al., 1998).  Human macrophages have also been 
shown to express cPLA2γ (Duan et al., 2001).  In the present study, immunohistochemical 
assays did detect the cPLA2 protein in the MDA-MB 231 and the MCF-7 cells.   It was not 
detected in the MCF-10A cells.  The cPLA2γ antisera blocked with its corresponding 
blocking peptide, and in specimens treated with AACOCF3 the cPLA2γ protein was not 
detected.   
The cPLA2γ isoform has been reported to be membrane bound and contains putative 
acylation and a C-terminal prenylation site that may regulate its membrane association 
(Underwood et al., 1998).  In mammalian cells, cPLA2γ is farnesylated and acylated, and 
immunohistochemical analyses have revealed that it co-localizes with the mitochondria 
(Tucker et al., 2005).  Although the data from both the MDA-MB 231 and the MCF-7 cells 
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strongly suggest the presence of cPLA2γ, further investigation is necessary to ascertain the 
precise location of cPLA2γ in these cells.  A corresponding study examining the cPLA2 
expression by Western blotting was performed using microsomal preparations and whole cell 
lysates (data not shown) from the MDA-MB 231, MCF-7, and MCF-10A cells.  Similar to 
the other cPLA2 isoforms, cPLA2γ was not detected in any of the cell lines.  Cytokines 
induce the release of cPLA2γ dependent AA in the HEK293 cells (Murakami et al., 2003).  
Earlier studies in this laboratory indicated that TNF-α upregulates cPLA2γ mRNA and 
protein expression in the MCF-7 cells (Maricica Pacurari, 2006).  No such effect on the 
protein was found in this study in the MDA-MB 231, MCF-7 or the MCF-10A cells treated 
with either TNF-α or IL-1β.  The basis of this discrepancy is unclear and additional efforts 
will be required for clarification.   
A subsequent study was performed to assess the cPLA2 isozyme expression in 
surgically removed human cancerous breast tissue.  Inconclusive results were obtained from 
the Western blot analyses performed.  There are the possibilities of protein degradation or 
undetectable expression of the cPLA2 isoforms in light of these results.  Future experiments 
involving immunohistochemical techniques may detect the expression of the cPLA2 
isozymes in surgically removed breast cancer tissue.   
 The studies described in this thesis, indicate the presence of the cPLA2 isozymes -α,  
-β and -γ in the breast cancer cell lines, MDA- MB 231 and MCF-7, but not in the non-
transformed breast cell line MCF-10A.  Stimulation by Ca
2+
 ionophore A23187 caused 
relocation of the Ca
2+
 dependent cPLA2 isoforms, -α and -β, within the MDA-MB 231 and 
the MCF-7 cells.  cPLA2α, -β and -γ peptide blocked antisera failed to detect the respective 
cPLA2 isoforms in the cancer cell lines, suggesting that the detected signal was cPLA2 
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isoform specific.  This was supported by the results from AACOCF3 pretreatment where the 
cPLA2 isoform signals were lost upon treatment with the inhibitor.  cPLA2α is believed to be 
the principal enzyme responsible for AA release for eicosanoid biosynthesis.  However, 
cPLA2β and cPLA2γ, each of which displays ~30% sequence homology to cPLA2α, may also 
be associated with AA release and eicosanoid synthesis in the cell lines tested.  AACOCF3, 
the cPLA2α inhibitor, caused a decrease in cPLA2β and cPLA2γ signals as well.  This is an 
observation that, to our knowledge, has not been reported elsewhere.  Whether or not the 
cPLA2 isozymes are expressed in breast cancer tissue remains undetermined and further 
investigations are warranted. 
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FIGURES 
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Fig. 2:  Characterization of cPLA2 antisera:  A. The schematic location of 
cPLA2peptide selected as potential antigen for antibody generation  relative to the cPLA2 
amino acid (aa) sequence (not drawn to scale) (Adapted from Song et al., 1999).  B. 
cPLA2antibody titer determination by Western analysis.  5 g of purified MBP-cPLA2 
peptide was loaded in each lane.  cPLA2 antibody dilutions were used as follows:  Lanes 1, 
2: 1:50;  Lanes 3,4: 1:100;  Lanes 5,6:1:500;  Lanes 7,8:1:1000.  Arrows indicate the selected 
antibody titers used in subsequent studies (Results are representative of 3 trials).  C. cPLA2 
Specificity Analysis.  Bacterially expressed and amylose beads purified cPLA2specific 
fragment with maltose binding (MBP) epitope was used for this analysis.  Amounts of MBP-
cPLA2 peptide used are indicated in the figure.  The antibody dilution used was 1:500.  
Assays with the purified MBP peptide did not produce any results (Results are representative 
of 3 trials).  D. cPLA2 Crossreactivity Analysis.  Bacterially expressed and amylose beads 
purified cPLA2isozyme specific fragments with maltose binding epitopes were used in this 
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analysis.  α: MBP-cPLA2 (411 - 442);  βI: MBP-cPLA2(1 - 57) or cPLA2 ;  βII: MBP-
cPLA2II (808-829) or cPLA2;  γ: MBP-cPLA2 (307 - 327);  MBP: MBP alone.  g 
peptide was used in the analysis. The antibody dilution used was 1:500. (Results are 
representative of 3 trials). 
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Fig. 3: Basal expression of cPLA2 isoforms in MDA-MB 231, MCF-7 and MCF-10A 
cells.  Total protein was prepared as described in Materials and Methods and 50 µg per lane 
was used to assay for cPLA2cPLA2andcPLA2isozyme expressionFor cPLA2 
isozyme expression microsomal extracts were prepared as described in Materials and 
Methods and 50 µg per lane was used.  (A) Tested against cPLA2α antibody (1:50).  (B) 
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Tested against pre-incubated cPLA2α antibody (1:50).  (C) Tested against cPLA2βI antibody 
(1:50).  (D) Tested against pre-incubated cPLA2βI antibody (1:50).  (E) Tested against 
cPLA2βII antibody (1:40).  (F) Tested against pre-incubated cPLA2βII antibody (1:40).  (G) 
Tested against cPLA2γ antibody (1:40).  (H) Tested against pre-incubated cPLA2γ antibody 
(1:40) (Results are representative of 3 trials for each isozyme).  
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Fig. 4:  Effects of TNFand IL–1 on cPLA2 isozyme expression in MDA-MB 231 cells: 
MDA-MB 231 cells were treated with a control for steroid hormone treatment (0.1% ethanol) 
in lane 1, TNFnM) in lane 2 and IL–1pM) in lane 3.  Total protein was prepared 
as described in Materials and Methods and 50 µg per lane was used to assay for cPLA2and 
cPLA2isozyme expressionFor cPLA2 isozyme expression, microsomal extracts were 
prepared as described in Materials and Methods and 50 µg was used.  A) Tested against 
cPLA2α antibody (1:50).  (B) Tested against pre-incubated cPLA2α antibody (1:50).  (C) 
Tested against cPLA2βI antibody (1:50).  (D) Tested against pre-incubated cPLA2βI antibody 
(1:50).  (E) Tested against cPLA2γ antibody (1:40).  (F) Tested against pre-incubated cPLA2γ 
antibody (1:40) (Results are representative of 3 trails for each isozyme). 
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Fig. 5:  Effects of TNFand IL–1 on cPLA2 isozyme expression in MCF-10A cells: 
MCF-10A cells were treated with control for steroid hormone treatment (0.1% ethanol) in lane 
1, TNFnM) in lane 2, or IL–1pM) in lane 3.  Total protein was prepared as 
described in Materials and Methods and 50 µg per lane was used to assay for cPLA2and 
cPLA2isozyme expressionFor cPLA2 isozyme expression, microsomal extracts were 
prepared as described in Materials and Methods and 50 µg per lane was used.  (A) Tested 
against cPLA2α antibody (1:50).  (B) Tested against pre-incubated cPLA2α antibody (1:50).  
(C) Tested against cPLA2βI antibody (1:50).  (D) Tested against pre-incubated cPLA2βI 
antibody (1:50).  (E) Tested against cPLA2γ antibody (1:40).  (F) Tested against pre-incubated 
cPLA2γ antibody (1:40) (Results are representative of 3 trials for each isozyme). 
  
66 
 
 
 
Fig. 6: Immunohistochemical detection of cPLA2α and cPLA2βI in MDA-MB 231 cells. 
Cells were grown on gelatin coated coverslips, fixed and probed with cPLA2 isozyme antibody 
as indicated in Materials and Methods.  The secondary antibody used was goat-anti-rabbit IgG 
coupled with Alexafluor 488.  (A) Detection and distribution of cPLA2α.  cPLA2α antibody 
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(1:50) was used in this study.  (B) cPLA2α probed with the cPLA2α antibody pre-incubated 
with the specific blocking peptide (1:50).  (C) Detection and distribution of cPLA2β.  cPLA2βI 
antibody (1:50) was used in this study.  (D) cPLA2β probed with the cPLA2βI antibody pre-
incubated with the specific blocking peptide (1:50).  (E) Cells probed with Alexafluor 488 
secondary antibody.  Images were taken using 40X oil immersion objective (Results are 
representative of 2 trails).  
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Fig. 7: Immunohistochemical detection of cPLA2βII and cPLA2γ in MDA-MB 231 cells. 
Cells were grown on gelatin coated coverslips, fixed and probed with cPLA2 isozyme antibody 
as indicated in Materials and Methods.  Secondary antibody was goat-anti-rabbit IgG coupled 
with Alexafluor 488.  (A) Detection and distribution of cPLA2β.  cPLA2βII antibody (1:40) 
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was used in this study.  (B) cPLA2β probed with the cPLA2βII antibody pre-incubated with the 
specific blocking peptide (1:40).  (C) Detection and distribution of cPLA2γ.  cPLA2γ antibody 
(1:40) was used in this study.  (D) cPLA2γ probed with the cPLA2γ antibody pre-incubated 
with the specific blocking peptide (1:40).  (E) Cells probed with Alexafluor 488 secondary 
antibody.  Images were taken using 40X oil immersion objective (Results are representative of 
2 trails). 
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Fig. 8: Immunohistochemical detection of cPLA2α, cPLA2β and cPLA2γ in MCF-7 cells. 
Cells were grown on gelatin coated coverslips, fixed and probed with cPLA2 isozyme 
antibody as indicated in Materials and Methods.  Secondary antibody used was goat-anti-
rabbit IgG coupled with Alexafluor 488.  (A) Detection and distribution of cPLA2α.  cPLA2α 
antibody (1:50) was used in this study.  (B) cPLA2α probed with the cPLA2α antibody pre-
incubated with the specific blocking peptide (1:50).  (C) Detection and distribution of 
cPLA2β.  cPLA2βI antibody (1:50) was used in this study.  (D) cPLA2β probed with the 
cPLA2βI antibody pre-incubated with the specific blocking peptide (1:50).  (E) Detection and 
distribution of cPLA2γ.  cPLA2γ antibody (1:40) was used in this study.  (F) cPLA2γ probed 
with the cPLA2γ antibody pre-incubated with the specific blocking peptide (1:40).  (G) Cells 
probed with Alexafluor 488 secondary antibody.  Images were taken using 40X oil 
immersion objective (Results are representative of 2 trials).  
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Fig. 9: Immunohistochemical assay of cPLA2α, cPLA2β and cPLA2γ in MCF-10A cells. 
Cells were grown on gelatin coated coverslips, fixed and probed with cPLA2 isozyme antibody 
as indicated in Materials and Methods.  Secondary antibody used was goat-anti-rabbit IgG 
coupled with Alexafluor 488.  (A) Distribution of cPLA2α.  cPLA2α antibody (1:50) was used 
in this study.  (B) Distribution of cPLA2β.  cPLA2βI antibody (1:50) was used in this study.  
(C) Distribution of cPLA2γ.  cPLA2γ antibody (1:40) was used in this study. (D) Cells probed 
with Alexafluor 488 secondary antibody.  Images were taken using 40X oil immersion 
objective (Results are representative of 2 trials). 
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Fig. 10: Modulation of cPLA2 isozymes in MDA-MB 231 cells by AACOCF3.  
AACOCF3, an analogue of arachidonic acid has been reported to be a cPLA2α inhibitor.  (A) 
Detection of cPLA2α after treatment with 0.05% ethanol (vehicle).  The cPLA2α antibody 
dilution used was 1:50.  (B) cPLA2α after treatment with AACOCF3 (10 µM for 15 mins).  
The cPLA2α antibody dilution used was 1:50.  (C) Detection of cPLA2β after treatment with 
0.05% ethanol (vehicle).   The cPLA2βI antibody dilution used was 1:50.  (D) cPLA2β after 
treatment with AACOCF3 (10 µM for 15 mins).  The cPLA2βI antibody dilution used was 
1:50.  (E) Detection of cPLA2γ after treatment with 0.05% ethanol (vehicle).   The cPLA2γ 
antibody dilution used was 1:40.  (F) cPLA2γ after treatment with AACOCF3 (10 µM for 15 
mins).  The cPLA2γ antibody dilution used was 1:40.  Images were taken using 40X oil 
immersion objective (Results are representative of 2 trials). 
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Fig. 11: Modulation of cPLA2 isozymes in MCF-7 cells by AACOCF3.  (A) Detection of 
cPLA2α after treatment with 0.05% ethanol (vehicle).   The cPLA2α antibody dilution used 
was 1:50.  (B) cPLA2α after treatment with AACOCF3 (10 µM for 15 mins).  The cPLA2α 
antibody dilution used was 1:50.  (C) Detection of cPLA2β after treatment with 0.05% 
ethanol (vehicle).   The cPLA2βI antibody dilution used was 1:50.  (D) cPLA2β after 
treatment with AACOCF3 (10 µM for 15 mins).  The cPLA2βI antibody dilution used was 
1:50.  (E) Detection of cPLA2γ after treatment with 0.05% ethanol (vehicle).   The cPLA2γ 
antibody dilution used was 1:40.  (F) cPLA2γ after treatment with AACOCF3 (10 µM for 15 
mins).  The cPLA2γ antibody dilution used was 1:40.   Images were taken using 40X oil 
immersion objective  (Results are representative of 2 trials). 
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Fig. 12: Modulation of cPLA2α and cPLA2β isozymes by Ca
2+
 ionophore (A23187) in 
MDA-MB 231 cells.   (A) Distribution of cPLA2α after treatment with HEPES buffer with 
0.05% ethanol (vehicle).  The cPLA2α antibody dilution used was 1:50.  Images were taken 
using 40X oil immersion objective.  (B) Distribution of cPLA2α after treatment with A23187 
(5 µM for 5 mins).  The cPLA2α antibody dilution used was 1:50.  Images were taken using 
40X oil immersion objective.  (C) Distribution of cPLA2α after treatment with A23187 (5 µM 
for 5 mins).  The cPLA2α antibody dilution used was 1:50.  Images were taken using 60X oil 
immersion objective.  (D) Distribution of cPLA2β after treatment with HEPES buffer with 
0.05% ethanol (vehicle).  The cPLA2βI antibody dilution used was 1:50.  Images were taken 
using 40X oil immersion objective.   (B) Distribution of cPLA2β after treatment with A23187 
(5 µM for 5 mins).  The cPLA2βI antibody dilution used was 1:50.  Images were taken using 
40X oil immersion objective.   (C) Distribution of cPLA2β after treatment with A23187 (5 µM 
for 5 mins).  The cPLA2βI antibody dilution used was 1:50.  Images were taken using 60X oil 
immersion objective.  Arrows indicate distribution of cPLA2 isozyme within the cell after 
treatment with A23187 (Results are representative of 2 trials). 
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Fig. 13: Modulation of cPLA2α and cPLA2β isozyme distribution by Ca
2+
 ionophore 
(A23187) in MCF-7 cells.   (A) Distribution of cPLA2α after treatment with HEPES buffer with 
0.05% ethanol (vehicle).  The cPLA2α antibody dilution used was 1:50.  (B) Distribution of 
cPLA2α after treatment with A23187 (5 µM for 5 mins).  The cPLA2α antibody dilution used 
was 1:50.  (C) Distribution of cPLA2β after treatment with HEPES buffer with 0.05% ethanol 
(vehicle).  The cPLA2βI antibody dilution used was 1:50.  (D) Distribution of cPLA2β after 
treatment with A23187 (5 µM for 5 mins).  The cPLA2βI antibody dilution used was 1:50.  
Images were taken using 40X oil immersion objective.   Arrows indicate distribution of cPLA2 
isozyme within the cell after treatment with A23187 (Results are representative of 2 trials).  
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Fig. 14: Immunochemical assays of cPLA2 isozymes α, β and γ in human breast tumor 
sample I: Tumor sample I was diagnosed as an invasive ductal carcinoma.  Total protein was 
prepared as described in Materials and Methods and 20 µg protein was used in each of the 
above Western blots.  In each specimen, tumor preparation was loaded  in the left lane and  the 
protein  marker in the right lane.  A) Tested against cPLA2α antibody (1:50).  (B) Tested 
against pre-incubated cPLA2α antibody (1:50).  (C) Tested against cPLA2βI antibody (1:50). 
(D)  Tested against pre-incubated cPLA2βI antibody (1:50).  (E) Tested against cPLA2γ 
antibody (1:40).  (F) Tested against pre-incubated cPLA2γ antibody (1:40).  No detection of 
any cPLA2 isozyme was evident.  
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Fig. 15: Immunochemical assays of cPLA2 isozymes α, β and γ in human breast tumor 
sample II: Tumor sample II was diagnosed as an infiltrating ductal carcinoma.  Total protein 
was prepared as described in Materials and Methods and 30 µg protein was used in each of the 
above Western blots.  In each specimen, tumor preparation was loaded  in the left lane and  the 
protein  marker in the right lane.  (A) Tested against cPLA2α antibody (1:50).  (B) Tested 
against pre-incubated cPLA2α antibody (1:50).  (C) Tested against cPLA2βI antibody (1:50).  
(D)  Tested against pre-incubated cPLA2βI antibody (1:50).  (E) Tested against cPLA2γ 
antibody (1:40).  (F) Tested against pre-incubated cPLA2γ antibody (1:40).  No detection of 
any cPLA2 isozyme was evident. 
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Fig. 16: Immunochemical assays of cPLA2 isozymes α, β and γ in human breast tumor 
sample III: Tumor sample III was diagnosed as an infiltrating ductal adenocarcinoma.  Total 
protein was prepared as described in Materials and Methods and 4.8 µg protein was used in 
each of the above Western blots.  In each specimen, tumor preparation was loaded  in the left 
lane and  the protein  marker in the right lane.  (A) Tested against cPLA2α antibody (1:50).  
(B) Tested against pre-incubated cPLA2α antibody (1:50).  (C) Tested against cPLA2βI 
antibody (1:50).  (D) Tested against pre-incubated cPLA2βI antibody (1:50).  (E) Tested 
against cPLA2γ antibody (1:40).  (F) Tested against pre-incubated cPLA2γ antibody (1:40).  
No detection of any cPLA2 isozyme was evident. 
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Fig. 17: Immunochemical assays of cPLA2 isozymes α, β and γ in human breast tumor 
sample IV: Tumor sample IV was diagnosed as an invasive ductal carcinoma.  Total protein 
was prepared as described in Materials and Methods and 4 µg protein was used in each of the 
above Western blots.  In each specimen, tumor preparation was loaded  in the left lane and  the 
protein  marker in the right lane.  (A) Tested against cPLA2α antibody (1:50).  (B)  Tested 
against pre-incubated cPLA2α antibody (1:50).  (C) Tested against cPLA2βI antibody (1:50).  
(D) Tested against pre-incubated cPLA2βI antibody (1:50).  (E) Tested against cPLA2γ 
antibody (1:40).  (F) Tested against pre-incubated cPLA2γ antibody (1:40).  No detection of 
any cPLA2 isozyme was evident. 
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Fig. 18: Immunochemical assays of cPLA2 isozymes α, β and γ protein in human breast 
tumor sample V: Tumor sample V was diagnosed as an invasive ductal carcinoma.  Total 
protein was prepared as described in Materials and Methods and 8 µg protein was used in each 
of the above Western blots.  In each specimen, tumor preparation was loaded  in the left lane 
and  the protein  marker in the right lane.  (A) Tested against cPLA2α antibody (1:50).  (B) 
Tested against pre-incubated cPLA2α antibody (1:50).  (C) Tested against cPLA2βI antibody 
(1:50).  (D) Tested against pre-incubated cPLA2βI antibody (1:50).  (E) Tested against cPLA2γ 
antibody (1:40).  (F) Tested against pre-incubated cPLA2γ antibody (1:40).  No detection of 
any cPLA2 isozyme was evident. 
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